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GIZELLE SUSETTE BAKER. Cancer Dose-Response Modeling of Low Dose 
Radiation Exposure. (Under the direction of DAVID G. HOEL, Ph.D.). 
Many late effects from exposure to ionizing radiation, including cancers, have 
been described in the literature. The identification and quantification of radiation-induced 
health effects is an important and complex issue. Recommendations for radiation safety 
and protection from the International Commission on Radiological Protection are made 
using a linear no threshold risk model on epidemiological data. A major obstacle in this 
process is the limited availability of data to directly measure the health effects of 
radiation on human populations. One way to circumvent this problem IS to use 
experimental data from laboratory animals and extrapolate across species to man. 
The cancer incidence and mortality data from the Japanese atomic bomb survivors 
was adjusted for uncertainty that exists in the dose estimates, systematic error in the 
neutron dose estimates, and a dose-dependent relative biological effectiveness. A 
threshold term was included in the -Poisson regression model as a surrogate for 
nonlinearity in the dose response curve. The research suggests that the threshold 
improves the fit of the model for the solid tumor incidence, as well as the leukemia 
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incidence and mortality data (although the mortality data was not a significant 
improvement). 
In our study, B6CF 1 mice were used to assess the shape of the dose response 
curve and the effects of fractionation at low doses. The Cox proportional hazards model 
was used to as an empirical model, while the two-stage clonal expansion model was used 
as the biologically based cancer model in which infonnation on the carcinogenesis 
process is incorporated into the model. The two models resulted in similar descriptions 
of the dose response curves, cancer risks, neutron relative biological effectiveness and 
dose rate effectiveness factor associated with exposure to ionizing radiation. The 
analyses indicate that the dose response curve appears linear in the low dose region, and 
fractionation reduces the effectiveness of gamma exposure while increasing the 




The derivation of cancer risks from low dose and low dose rate exposures to 
ionizing radiation is important in the setting of standards for radiological protection. The 
problem is there are only a few human populations exposed at low to moderate dose rates 
in which direct estimates of cancer risk can be calculated. Therefore, most of the 
infonnation available today about cancer risks in human populations following exposure 
to ionizing radiation corne from extrapolating high dose, high dose rate studies. The 
Japanese atomic bomb survivor Life Span Study (LSS) data is a major source of a data 
for determining risk estimates of radiation-induces cancers (Fry and Sinclair 1987;Vaeth 
and Stram 1989). The issue that arises when modeling cancer risks at low doses using 
epidemiological methods is that it is nearly impossible to observe, with statistical 
confidence an increased cancer incidence due to exposure (National Council on Radiation 
Protection and Measurements 2001). Since error in dosimetry impact both the risk 
estimates and radiation protection standards, it is important to consider them in the 
modeling of this data. 
The radiation exposures that resulted from the two atomic bombs dropped in 
Japan are considered mixed exposures, since the survivors were exposed to a 
combination of gamma and neutron radiation. The uranium bomb used in Hiroshima 
generated a substantially higher dose of neutron as compared to the minimal neutrons 
delivered by the plutonium bomb in Nagasaki (Hollingsworth 1986;Roberts 1987). The 
difference in the bombs is important in that there is an inverse relationship between the 
risk coefficients for gamma rays and neutrons (Kellerer and Nekolla 1997). This 
relationship is obvious in that the excess mortality is made up of a neutron and gamma 
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ray component; and as the attribution due to neutrons increases the attribution of photons 
decreases. In previous analyses of for Radiation Effects Research Foundation (RERF) 
reports on the atomic bomb survivors, and for radiation protection purposes a linear dose 
response relationship has been assumed for low dose exposures of neutrons and photons. 
In recent years the possibility of non-linearities in the low dose region of the dose 
response curve has been a topic that has generated a lot of interest. Threshold models 
have been used as a surrogate for non-linearities, and in an analysis using the unadjusted 
dosimetry system 1986 (DS86) dose values, a threshold modeled significantly improved 
the fit of the model to the leukemia incidence data (Hoel and Li 1998). It was 
hypothesized that the improvement in fit with a threshold term could simply be the 
artifact of the errors associated with the dose estimates (Little 1999). Therefore, it will be 
important to see if the findings hold true after adjustments are made to the dose estimates. 
It is recognized that both systematic errors and uncertainty in the dose estimates 
may alter the shape of the dose response relationship and in effect the evidence for 
curvature in the dose response curve. The problem with the uncertainty in the dose 
estimates, also known as random error in the dosimetry, has been investigated (Gilbert 
1984;lablon S. 1971) and many papers have been published on the methods that have 
been developed to account for random error in the total dose (Little and Muirhead 1996, 
1997;Pierce et al. 1990). More recently, these methods have been modified to account 
for the error in the two subcomponents of the dose, gamma and neutron dose, separately 
(Little and Muirhead 2000;Pierce and Preston 2000). This allows for a better assessment 
of the contribution the neutron component of dose makes on the dose response curve, and 
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allows for the correction to be combined with a different relative biological effectiveness 
(RBE) values in calculating the weighted dose. 
The issue of a systematic underestimation of the neutron dose also has an impact 
on the shape of the resulting dose response curve. The issue arises when looking at 
experimental neutron activation measurements; these indicate that there are large 
discrepancies between the DS86 neutron estimates and the neutron activation 
measurements in Hiroshima. The initial discrepancies were noticed in thermal (slow) 
neutron activation measurements (Straume et al. 1992) and tentative corrections were 
made to bring the DS86 dose estimates in line with the thermal neutron measurements. 
Kellerer et al. (1997) investigated the effects of adjusting the dose estimates and found 
that although a linear model fit the data a purely quadratic function of gamma exposure 
was also consistent with the data. Recent improvements in accelerator mass spectrometry 
have allowed for the measurement of 63N i in copper samples to detennine the fast neutron 
fluences, which is more representative of the exposure doses (Ruhm et al. 2000). 
Therefore, to realistically estimate the neutron contribution, corrections should be made 
to bring the DS 86 neutron estimates in line with the fast neutron activation measurements 
instead of the slow neutron activation measurements (Kellerer and Walsh 2001;N ational 
Research Council 2001). 
The neutron relative biological effectiveness is the estimate of how much more 
efficient high-LET radiations are at causing at set biological effect compared to photons 
per unit of absorbed dose (Britten et al. 2001). Therefore, weighting factors, that depend 
on the neutron energy, have been adopted to best represent the RBE of low doses with 
regard to stochastic late effects (Kellerer and Nekolla 1997). In radiobiology the unit 
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gray (Gy) is used to represent joules per kilogram (J/kg), the individual dose 
measurements, and sieverts (Sv) are the unit used to represent the dose equivalent, when 
the difference in effectiveness (RBE) is accounted for. In the assessments of cancer risks 
due to radiation exposure calculated based on the atomic bomb survivor data the average 
dose equivalents are calculated for each stratum using a constant RBE of 10 (Pierce et a1. 
1996b). Radiation biology studies have shown that RBE is not a constant value; instead 
it varies with radiation dose, so that the larger the dose the smaller the RBE (Straume et 
al. 1992). The large effects of small errors in the low dose region make it important to 
consider all known components that effect dose estimates including a variable REE when 
modeling cancer risks. 
The dose-response relationship between exposure to ionizing radiation and cancer 
risks in humans has primarily been analyzed using Poisson regression techniques, 
although the use of biologically based models has gained attention in recent years (Kai et 
a1. 1997). The model is not focused on the low dose behavior, but has provided 
perspective on the temporal behavior of risk after acute exposures to ionizing radiation 
(Little 1999). The atomic bomb data is a high dose high dose rate data set in which 
subj ects were exposed to acute doses of mixed radiation; therefore, the infonnation 
available is not sufficient to provide insight into the cancer effects of 
• exposure pattern - radiation quality, low doses, low dose rates, protracted or 
fractionated exposures 
• risk modifiers - including genetic differences as well as other factors 




(Cardis et al. 2001). 
Knowledge gained from experimental animal studies is used supplement the 
infonnation that is provided by the epidemiological data used in estimating the risks of 
radiation exposure on human populations. Evidence indicates that the magnitude of 
cancer effects varies with radiation quality, dose, dose rate, cancer endpoint, and other 
factors; that cannot be directly estimated from the human studies. Therefore, dose 
weighting factors have been calculated from in vivo and in vitro cell line studies and 
animal studies and are applied in risk assessment. 
2. SPECIFIC AIMS 
The goal of this research is to investigate the low dose region of the cancer dose 
response curve for exposure to ionizing radiation. The specific aims of this research are 
to: 
1.) To compare the fits of the threshold models before and after the incorporation 
of the appropriate dose adjustments are made for the uncertainty in the dose 
estimated and systematic error in the neutron component of dose. 
2.) To explore the effects of a dose dependent RBE on the shape of the dose 
response curve at low doses. 
3.) Investigate the similarities and differences in the dose response curve and risk 
estimates between the empirical survivor models and biologically based 
survivor models. 
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4.) Examine the effect of exposure pattern (dose fractionation and radiation 
quality) on the shape of the dose-response curves for total cancer, solid 
tumors, and leukemias using animal data. 
3. REVIEW OF LITERATURE 
3.1 Dose Uncertainty Adjustment 
The data available from RERF does not contain the true gamma and neutron 
doses (D)' and Dn respectively), because these values are unknown; the doses available in 
the LSS data are nominal doses (dy and dn - dose estimates) based on an elaborate dose 
reconstruction. Inherent in a dose reconstruction is a non-negligible amount of dose 
uncertainty, due to random and non-random errors in the reconstruction process (Kaul 
1989). Random error in the dose estimates have been shown to alter the shape of the 
dose response curve (Little and Muirhead 1996;Pierce et al. 1990), and result in the 
incorporation of a systematic bias in the risk estimates (Little and Muirhead 2000;Pierce 
et al. 1992), therefore nullifying any available evidence for linearity or curvilinearity 
(Stram 1989). 
The issue of dose uncertainty in the RERF dose estimates has been investigated, 
and it has been determined that the probable form and magnitude of the error follow a 
log-normal distribution with the coefficient of variation somewhere between 25 and 45% 
(Gilbert 1984;lablon S. 1971), although in the majority of studies that account for the 
uncertainty in the dose estimates it is assumed to be 35%. Methods developed in Pierce 
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et al. (1990, 1992) use the infonnation on the distribution of the of the uncertainty in the 
doses (log-nonnal), the assumed distribution of the true doses (Weibull) and the 
empirical distribution of the nominal doses in adjusting the total dose estimates (dy + 
10dn). The average true dose given the nominal dose (A vg[D I d]) is calculated for every 
cell in the data (Pierce et aL 1990, 1992) using 
Av [D I d] = L f(D,d)· D· tiD 
g Lf(D,d). ~D ' 
where 
e 8 D (02-1) {_ e DB2 }. {[IOg(D )-log(d j )]2 } 1 2 exp 1 exp 2 
20-
f(D,d) == ~ 
d j er v 21t 
These adjusted doses have been included in the most recent mortality data made available 
by RERF. When Avg[D I d] is used in place of the nominal dose so that the model so we 
are modeling A vg[A(D) I d] instead of A(D), but the estimated regression parameters 
(Little 2000). The problem with these corrections is that they require that the RBE be 
fixed at 10 and don't allow for a correction of the neutron doses. The methods developed 
by Pierce et al. can been generalized so that they are applied separately to the neutron and 
gamma components of the dose (Little and Muirhead 2000;Pierce and Preston 2000). 
3.2 Systematic Error in the Neutron Dose Estimates 
The DS86 was published in 1986 as the replacement for the previous dosimetry 
(T65D). The major change in the new dosimetry were in the neutron dose estimates in 
Hiroshima - the neutron doses were reduced from approximately 20% of the total dose to 
about 2% of the total dose while the gamma dose increased by a factor of 2 to 3.5 
depending on the distance from the hypocenter (Roberts 1987). The doses in Nagasaki 
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were also altered, although the changes were much smaller; the gamma dose was slightly 
reduced and the already minimal neutron doses further reduced. 
Even with these corrections in the neutron doses there still appear to be 
discrepancies with the more recent neutron activation measurements (Kellerer and Walsh 
2001). The new measurements indicate that the neutron component of dose has been 
systematically underestimated for distances beyond 1 to 1.5 kilometers (Straume et al. 
1992). Therefore, Straume suggests that in order to obtain more realistic estimates of the 
neutron contribution the neutron doses must be corrected upwards in line with the 
neutron activation measurements as a function of the distance from the hypocenter using 
the relationship 
K' = C(r)-K 
where K' is the corrected free in air kenna (measurement of radiation in the air), K in the 
uncorrected (DS86) free in air kerma, and C(r) is a correction factor that is a function of 
ground distance in kilometers from the hypocenter (Kellerer and N ekolla 1997). Since 
there is a direct relationship between free in air kenna and absorbed dose the relationship 
for between corrected and uncorrected dose is the same as for free in air kerma. 
Although the latest data on fast neutrons has not been published the relationship between 
the gamma and neutrons doses has been discussed (Kellerer and Walsh 2001;National 
Research Council 2001) and this relationship is used to calculate a tentative correction for 
the neutron activation measurements. 
Calculating the correction factor as a function of distance introduces a problem 
because there is no infonnation on distance from the hypocenter available in the data. 
Keller and Nekolla (1997) suggest that C(r) can be inferred from the magnitude of the 
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gamma component of dose, since dose and distance are related and the gamma dose is the 
most highly correlated dose since it is the least dependent on shielding factors. 
3.3 Dose Dependent RBE 
In previous analyses and reports on cancer risks based on the atomic bomb 
survivors it has been acknowledged that neutrons are more effective at producing the a 
biological effect than gamma radiation (Committee on the Biological Effects of Ionizing 
Radiation 1990;ICRP 1991;ICRU 1986;United Nations Scientific Committee on the 
Effects of Atomic Radiation 1994). In general the RBE for a given neutron dose is 
D 
defined as RBE n (D n ) = -Y , where Dy is the gamma dose required to produce the same 
Dn 
biological effect as a given dose neutron dose (Dn) (Britten et al. 2001). Most of the 
current infonnation on the neutron RBE comes from experimental animal data, not 
epidemiological data (Kellerer and Walsh 2001 ; Little 1997). Although it has been 
accepted in principle, that as dose decreases RBE must increase (Abrahamson 1989), it 
has not been incorporated in the analysis of the atomic bomb data until recently because 
the it cannot be calculated directly from the RERF data (Kellerer and Nekolla 1997). 
Therefore, in the cancer incidence and mortality reports on the atomic bomb survivors a 
fixed weighting factor of lOis used in place of a dose-dependent RBE (Mabuchi et al. 
1994;Preston et al. 1994;Ron et al. 1994;Thompson et al. 1994). 
Radiation biology studies of chromosomal aberration In human lymphocytes 
(Edwards et al. 1980) suggests that the dose-independent RBE results in an 
overestimation of the risk associated with the neutron component of dose (Rossi and 
Zaider 1990;Stram et aL 1993). Rossi and Zaider (1996) have shown that using the data 
obtained from human lymphocyte chromosomal aberration studies a reasonable dose-
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dependent RBEn can be calculated using the linear-quadratic model for the effects of 
gamma rays (aydy + J3ydy2) and a simple linear model for the neutrons (Undn) (Rossi and 
Zaider 1996). In the event of a mixed exposure the RBEn is dependent on both the 
neutron and gamma doses so that the REE is calculated as 
where ay= 1.57xl0-2 Gy-l, ~y= 5.0x10-2 Gy-2, and <Xn = 83.5xl0-2 Gy-l (Edwards et al. 
1980). 
The Poisson regression models given in the RERF reports are easily adjusted to 
allow for a variable RBE with an adjustment for the dose uncertainty and the neutron 
correction factor corrected dose so that the total dose would be d = dy + RBE( dy,dn)'dn, 
where the d is the Avg[(Dy + RBE(Dy,Dn)'Dn) I dy, dnJ and dn is corrected in line with the 
neutron activation measurements. Using these methods the RBE in the data ranges from 
2.3 at approximately 500 meter from the hypocenter to values as high as 53 at further 
distances from the hypocenter (Pierce et a1. 1996a;Rossi and Zaider 1996). 
3.4 Two-Stage Clonal Expansion Model 
The goal of biologically based dose-response modeling is to used information 
obtained from basic science to inform a quantitative models of a disease process 
(Moolgavkar et al. 1988). Most biologically based carcinogenesis models are stochastic 
population models that describe the carcinogenesis process as the temporal evolution and 
growth of cells in several distinct stages. The two-stage clonal expansion model is the 
mathematical idealization of the initiation-promotion-progression theory of 
carcinogenesis (Moolgavkar 1986). 
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In order to apply the two-stage clonal expansion model many assumption must be 
made about the cells, their behavior in the different stages and the endpoint of interest. It 
is assumed that at any given time in the study period there is a large, constant number of 
somatic cells (Xo) that are susceptible to genetic transfonnation, the initiated cells «Xl(t» 
reproduce in a stochastic manner, and that once a malignant cell (X2(t» is formed it will 
inevitably become an observable tumor (Kopp-Schneider et al. 1994;Nakamura and Hoel 
2002;Shennan and Portier 1997). 
Normal 
Cells [Xo] 
( Initiation ~ 
Initiated 
CeUs [Xl(t)] 
__ ..."A ...... __ ..... 




Figure 1 - The two-stage clonal expansion model where J..lI is the mutation rate of normal cells (per unit 
time); J.l2 is the mutation rate of initiated cells (per unit time per cell); J3is the birth or replication rate of 
initiated cells (per unit time per cell); and 0 is the death or differentiation rate (per unit time per cell). 
The model consists of four time-independent parameters J.l), J.12, (3, 5 seen in 
Figure 1. Each nonnal cell has a non-zero probability of undergoing a transformation 
into an initiated cell at a constant mutation rate of J.ll per unit time. Where the mutation 
rate is calculated as the product of the transition rate per unit time per cell and the number 
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of nonnal cells, so that Jl1 =v Xo. Any agent that enhances the probability of such an 
event is referred to as an initiator. Through replication, initiated cells can develop into 
clones of initiated cells at a rate of ~ per unit time per cell, differentiate or die at a rate of 
B per unit time per cell, or they can be transform into a malignant cell at a transition rate 
of Jl2 per unit time per cell (Kopp-Schneider et al. 1994). Any agent that results in an 
increase in the difference between the replication rate (13) and the differentiation rate (8), 
the net proliferation rate, is referred to as a promoter (Heidenreich et al. 1997). Once a 
malignant cell develops, it loses growth control and in a relatively short period of time 
will become a tumor; therefore, the fonnation of a single malignant cell is identified with 
the development of cancer (Heidenreich et al. 1997 ;Moolgavkar 1986). 
The model's parameters (8) are always positive so a log-linear transfonnation is 
applied to each parameter, 
where the total accumulated gamma or neutron dose is represented as D, a is a constant 
term, and bo and bI are regression coefficients. Due to the lack of identifiability that has 
been shown when estimating the four parameters from tumor incidence data (Hanin and 
Yakovlev 1996;Heidenreich et al. 1997), the parameter space must be reduced. This can 
be accomplished by fixing a parameter to a set rate, setting the transition rates equal to 
another (v = J.!2) or the replication rate equal to the differentiation rate (~ = 0), or 
reparameterizing the parameter space. It has been shown that the parameter estimates a 
MLE estimate can be generated using a combination of reparameterization and setting the 
differentiation rate equal to zero (8=0) so that 
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where the "*,, is used to denotes the parameters that are conditioned on ()=o. Maximum 
likelihood estimates (MLE) of the parameters are obtained using the reparameterized 
conditional likelihood equation as described in the appendix of Paper II and Paper Ill. 
More details on this method and a detailed comparison of the conditional and original 
likelihood are discussed in Nakamura and Hoel (unpublished paper). 
4. DATA SETS 
4.1 RERF Atomic Bomb Survivorship Data 
The extended Life Span Study (LSS) is the follow-up of the cohort of atomic 
bomb survivors in Hiroshima and Nagasaki. The doses included in this data set are the 
most recent estimates using the Dosimetry System 1986 (DS86). This study can be 
broken into parts; in this study we are interested in both the incidence and mortality data 
sets for solid tumors and leukemia. 
The solid tumor incidence data consists of all survivors that were alive as of 
January 1, 1958 and follows them through December 31, 1987. This data contains 79, 
972 people with a total of 1,950,567 person years at risk after survivors were excluded 
because they were not in either of the cities at the time of the bombings, their vital 
statistics were not available, they had DS86 doses greater than 4 Gy, or they had cancer 
prior to January 1, 1958 (Thompson et al. 1994). Tumor cases were determined by 
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matching this data with the Hiroshima and Nagasaki Tumor Registry where 8613 cases of 
solid cancer were reported (Hoel and Li 1998). 
For the leukemia incidence data the cohort includes all survivors that were alive 
as of October 1, 1950 and follows them through December 31, 1987, including 86,293 
persons contributing 2,554,000 person years at risk, after elimination of survivors in 
which vital statistics were unattainable (n=45), DS86 doses were unavailable (n=71 03), 
DS86 doses were greater than 4 Gy (n=262), and people with cancer prior to October 1, 
1950 (n=38) (Preston et al. 1994). This cohort is matched with the Leukemia Registry 
where there are a total of 339 reported cases of leukemia (Hoe! and Li 1998). 
The most recent follow up for the cancer mortality includes data from 1950 
through 1990, which includes an additional 10,500 more survivors with recently 
estimated doses (approximately 550,000 person-years) bringing the number of survivors 
to 86,572. There are 7827 cancer deaths of which 7578 are solid tumors and 249 are 
leukemia (Pierce et al. 1996b). 
4.2 JANUS Mouse Data 
The majority of the Argonne National Laboratory (ANL) studies, including the 
JANUS program, were designed to study the biological consequences of occupational 
levels of exposure to radiation on young adult animals (onset of exposure was at 
approximately 100 days of age). Between 1971 and 1992 the JANUS program at the 
Biological and Medical Research Division of Argonne National Laboratory compiled a 
database on the responses of both male and female Fl hybrid B6CFl mice (a cross 
between C57BL/6Jani ad BALB/cJAnl mice) to external whole body irradiation (Carnes 
and Grahn 1991). The mice were either exposed to fission neutrons (mean energy 0.85 
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MeV) or 60Co y-rays over a range of total doses delivered as either a single exposure or 
protracted exposures. Three basic patterns of exposure were investigated: (1.) single 
exposures, (2.) 24 once-weekly exposures and (3.) 60 once-weekly exposures. All 
irradiations were terminated at predetennined total doses, with the dose calculated at the 
midline of the mouse. The mice were then followed for the rest of their natural lives; at 
which point pathology and histology reports were used to detennine the cause of death 
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ABSTRACT: 
Cancer incidence and mortality data from the cohort of Japanese atomic bomb 
survivors has been adjusted for uncertainty that exists in the dose estimates, systematic 
error in the neutron dose estimates, and a dose-dependent relative biological 
effectiveness. Once the adjustments were incorporated in the dose estimates the data was 
analyzed to allow for the possibility of a threshold dose response. The dose response 
models that were fit to the data were the same models used in the original papers. 
A threshold term was included in the model with possible threshold values ranging from 
o to 0.35 Sv. These analyses suggest that for the A-bomb solid tumor and leukemia 
incidence data a threshold term significantly improves the fit to the purely linear or linear 
quadratic model. The results from the mortality data suggests that the leukemia data 
agree more with the threshold model than the linear quadratic model although the linear 
quadratic model is statistically equivalent, while the solid tumor data does not suggest 
any improvement with a threshold. 
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INTRODUCTION: 
Radiation protection agencies estimate radiation-induced cancer risks based on 
epidemiological studies of the Hiroshima and Nagasaki A-bomb survivors., medically 
irradiated patients, and occupational cohorts using the traditional linear no-threshold 
model. Debates on the scientific basis of the linear hypothesis have appeared in recent 
literature (Goldman 1996;National Council on Radiation Protection and Measurements 
2001). The linear no-threshold assumption has been adopted as a "pragmatic guideline in 
the absence of scientific certainty" because the complexities of cell responses at low 
doses cannot be resolved with epidemiological studies. Recent observations-such as 
genomic instability, bystander effect, and adaptive response are complexities that can 
modify the response at low doses, which if inducible in humans may invalidate some of 
the arguments that favor the linear no-threshold model (Kellerer and Nekolla 2000). 
The Japanese A-bomb survivor Life Span Study (LSS) cohort is the principal 
dataset used in assessing the cancer risks following exposure to ionizing radiation (United 
Nations Scientific Committee on the Effects of Atomic Radiation 1994). This population 
was exposed at high dose rates; therefore, the risk estimates must be extrapolated to 
derive estimates of cancer risks for the general public and occupational groups who are 
exposed to relatively low-dose protracted exposures. Models have been developed to 
extrapolate between high and low doses from both acute exposure and chronic or 
protracted exposures, and across time (Cardis et al. 2001). The problem is that these 
models inevitably introduce uncertainty into the estimates and have been the center' of 
debate for many years. 
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It is generally accepted that high dose, high dose-rate radiation induced cancer 
data are well described by a linear dose-response, the issue of interest in radiation risk 
assessment is the shape of the dose-response curve at low-doses. The problem is that 
non-linearities are almost impossible to observe or rule out at low-doses in 
epidemiological data (National Council on Radiation Protection and Measurements 
2001). This is because the cancer risks at low doses are too small to observe and 
confounders exist that cannot be controlled for in human populations. There is also the 
issue of uncertainty and error in the dose estimates and their potential impact on the dose-
response curve. Studies have shown that errors in the dose estimates can substantially 
alter the shape of the dose-response relationship, thereby nullifying any evidence for 
possible non-linearity in the dose-response (Little and Muirhead 2000). The issue of 
uncertainty in the Radiation Effects Research Foundation (RERF) data has been 
investigated (1 ablon S. 1971 ;Pierce et a1. 1990;Little and Muirhead 1997,2000). The 
presence of random errors in the dose estimates is from the uncertainty that is involved 
with any dose reconstruction and the bias introduced by the uncertainty in the survivors" 
location results in an overestimation of dose, and in tum, an underestimation of the 
radiation effect in dose-response analyses (Pierce et al. 1990). 
Another issue of concern with the current dose estimates used by RERF is that 
discrepancies exist between the calculated and the experimental neutron activation 
measurements. Experimental activation measurements of thennal (slow) and fast 
neutrons from 36Cl and 63Ni respectively suggest that a readjustment of the neutron doses 
is needed (Kellerer and Nekolla 1997;Kellerer and Walsh 2001;Straume et a1. 1992). 
These measurements revealed a systematic underestimation of the neutron component in 
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the dose estimates, especially at smaller doses (survivors beyond 1 kIn) (Rossi and Zaider 
1996;Little and Muirhead 2000). Recent advancements in accelerator mass spectrometry 
have made it possible to detennine the fast neutron fluences in Hiroshima using 63N i 
measurements in copper. Preliminary 63N i measurements have discounted the earlier 
tentative correction based on slow neutron activation measurements using 36C l. The 
unpublished 63N i activation measurement data are unconfirmed, although the relationship 
between neutron and gamma doses was discussed by the National Research Council 
(National Research Council 2001). 
The acute effects of neutron exposure are known from radiobiological studies, 
while their capability to produce late effects such as cancer, are not known from human 
observation. The most reliable infonnation on the late effects of neutron exposure comes 
from experimental animal studies, but due to the uncertainty in these results cannot be 
directly extrapolated to man. Since neutrons are the more effective ionizing radiation, a 
lower absorbed dose of neutrons than ,,(-rays is needed to produce the same biological 
effect, therefore a relative biological effectiveness (RBE) value is used in calculating the 
cancer risk estimates of neutrons and y-rays (Edwards 1999). The dose equivalent, 
measured in Sieverts (Sv), is simply the product of the RBE and the absorbed dose and 
results in a risk estimate that can be applied equally to the neutrons and ,,(-rays. The 
major analyses of the LSS data have assumed a constant weighting factor of 10 or 20 for 
the neutron RBE, even though radiation biology has shown that the neutron RBE 
increases with decreasing dose (Rossi and Zaider 1996). The problem is that RBE cannot 
be extracted with any certainty directly from epidemiological data (Edwards 1999), an 
attempt to calculate RBE using the A-bomb data resulted in and estimated RBE of 
- 28 -
6.1 Corrections in the Atomic Bomb Data to Examine Low Dose Risk 
70 (+50) (Zaider 1991). Rossi and Zaider (1996) and Pierce et a1. (1996) present 
methods using parameters extracted from human lymphocyte aberration data to calculate 
a dose-dependent RBE that can be applied to the A-bomb data. 
Analyses of the unadjusted dose estimates have indicated using linear threshold 
models (as a surrogate for non-linearity) that the addition of a threshold tenn significantly 
improved the linear-quadratic model dose response model for leukemias (Hoel and Li 
1998). It has since been suggested that this finding is an artifact of the uncertainties that 
exist in the dose estimates; and if they were accounted for, there would be no evidence 
for a threshold in the linear-quadratic model (Little 1999). 
The purpose of this paper is to reinvestigate the threshold dose response models 
after simultaneously adjusting for the uncertainty in the dose estimates, the systematic 
underestimation of the neutron component as a function of distance from the hypocenter, 
and a dose-dependent RBE. Specifically we will evaluate the models with the original 
uncorrected dose estimates, doses corrected for both the uncertainty and systematic error 
in the neutron dose estimates (using the new fast neutron activation measurement) with a 
fixed (RBE = 10) and a dose-dependent RBE. 
MATERIAL AND METHODS: 
The Study Population 
The data being used in these analyses is the publicly available cancer incidence 
and mortality data of the RERF's LSS cohort with doses less than 4 Gy. The solid tumor 
incidence data includes the 79,972 survivors of the cohort who were alive as of January 
1, 1958. The solid tumor cases were determined by matching the survivor data with the 
Hiroshima and Nagasaki Tumor Registry-as of December 31, 1987 a total of 8,613 
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cases were found (Thompson et al. 1994;Mabuchi et al. 1994). The leukemia incidence 
data includes 86,293 survivors who were followed from October 1, 1950 through the end 
of December 1987, matched with the Leukemia Registry for a total of339 leukemia cases 
(Preston et al. 1994). The most recent mortality data has an extended follow-up through 
1990 and uses death certificate data for cancer mortality-this cohort includes 86,572 
survIvors with 7,578 cases of cancer, including 249 cases of leukemia (Pierce et al. 
1996b). 
Statistical Methods 
Poisson regression methods similar to those used in the original studies by Preston 
et al. (1994) and Thompson et al. (1994) are used in the following analyses. This 
approach divides the data into cells based on city, gender, age-at-exposure, follow-up 
time, and weighted organ doses. Using Poisson regression models for cancer incidence 
assumes that the number of cases in each of the cells is a Poisson random variable with 
the mean and variance equal to the product of the person years at risk (PYR) and the 
incidence rate. AMFIT (Preston et al. 1991) is used to fit the model to the data, 
calculating the deviance, as a measure of the goodness of fit. The deviance is distributed 
approximately X2 with degrees of freedom equal to the difference in the number of cells 
and the number of parameters included in the model. The addition of a threshold tenn 
significantly improves the models if the deviance is reduced by a value greater than the 
critical value ofaX2 distribution with 1 degree of freedom (3.84 for a=O.05). 
The general class of models for the solid tumor incidence, A(D), and the subtypes 
of solid tumors are of the fonn 
A (D ) = A. (c , S , a, y ). [I + ERR (D, e, s, a )] , 
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where ACe, s, a, y) is the background incidence rate that depends on city (c), sex (s), 
attained age (a), and year (y). The other term in the model is the excess relative risk 
(ERR) which is modeled as a function of the true total dose (D), where the total dose is 
made up of the dose of y-rays (Dr) combined with the product of an RBE value and the 
neutron dose (Dn), age-at exposure (e), sex (s), and attained age (a). 
The leukemia incidence models are similar but are modeled using excess absolute 
risk (EAR) : 
A(D) = A.(c, s, a,y) + EAR(D, e, s, t), 
where t is the time since exposure. The models used in these analyses are those used in 
the original studies for solid tumor incidence by Thompson et a1. (1994), leukemia 
incidence by Preston et a1. (1994), and mortality by Pierce et a1. (1996). 
Dose thresholds are added to a model OfA(D) by defining the cancer rate as 




where do is the given threshold dose (Hoel and Li 1998). 
The gamma and neutron doses (dr and dn) available in the data are estimated doses 
because the true doses (Dr and Dn) are not known. It has been shown that by replacing 
A(D) with the average [A.(Dld)] in fitting the model, 
avg lA(D y' D n ~ d y' d n )J = A(C, s, a, y ). b + ERR (D y' D n , e, s, a)J, 
the parameter estimates are still approximately unbiased. This method is comparable to 
the methods used by Pierce et al. (1990) and Little and Muirhead (1996, 1997, 2000). In 
this analysis, the errors in the neutron and gamma dose estimates are accounted for 
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separately, similar to Little and Muirhead (2000), where the parametric form of the true 
dose is the probability of a true dose exceeding any value D and is given by the Weibull 
distribution exp(- 9 1 D
8
2 ). The parameters 8 1 and 92 are found for each combination 
radiation type, so that the resulting distribution matches that of the estimated doses 
(Pierce et al. 1990;Pierce et aL 1991). The distribution of the estimated dose given the 
true dose, f( diD), is assumed to be log-nonnal with median D and coefficient of variation 
d J which is approximately equal to the standard deviation of log(d). A log-normal model 
with a geometric standard deviation (GSD) of 30% to 40% was suggested based on the 
nature of the major sources of uncertainty in the dose estimates (Jablon S. 1971). The 
results in this paper are based on the log-nonnal 35% error model. 
Since the DS86 neutron dose estimates may be systematically underestimated, a 
tentative correction was used to bring the neutron doses in line with the measurements of 
activation by the slow neutrons. The work from Straume et al. (1992) and Kellerer and 
Nekolla (1997) suggests the following relationship: 
d~ == C(r)d n 
where d~ is the corrected mean neutron dose and C(r) is the correction factor which is a 
function of the distance (r) from the hypocenter of the bomb, measured in kilometers. 
Since the RERF data set does not contain data on distances from the hypocenter, they 
must be inferred from the relationship between dose and distance as given in Table 40 of 
Kerr et al. (1987) and the mean shielding factors given in Pierce et al (1996a). The 
relationship between gamma dose and distance is less dependent on the shielding than the 
neutron dose (Kellerer and Nekolla 1997), and therefore used as the surrogate for 
distance in the correction factor C(r). We used very similar methods in calculating a 
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correction factor to bring the neutron doses in line with the fast neutron measurements. 
This correction is shown as the ratio of the neutron to gamma dose in Figure 1. 
The importance of a dose-dependent RBE in analyzing the A-bomb data is 
another issue that has been debated. Although most studies have applied dose-
independent RBE's, radiation biology suggests the need for a dose-dependent RBE 
(Rossi and Zaider 1996), which can be calculated frqm human lymphocyte chromosomal 
aberration data (Edwards et al. 1980). Since the exposures in Hiroshima and Nagasaki 
were a combination of y-rays and neutrons, both doses must be used in calculating the 
neutron RBE. Using the assumptions of Rossi and Zaider (1996) and the equation for an 
RBE of mixed exposure from Pierce et al. (1996), 
u., [( 2f3., J RBE(D D) = . - 1 + - . D + 
Y' n 2A D Y 
Py n u y ( 
2~y J2 4J3.,<X n 1 l+--·D + ·D a Y a 2 n 
Y y 
we can calculate an approximate dose-dependent RBE for each dose. In the RERF data 
sets, small neutron doses (less than 0.001 Gy) are set equal to zero. This problem does 
not affects risk estimates when the typical RBE values of 10 and 20 are used in 
calculating dose; however, it has been shown that when the RBE is dependent on dose the 
smaller doses result in larger RBEs and the problem becomes appreciable. To fill in the 
missing values of neutrons, a combination of the mortality and incidence data was used to 
determine the average overall relationship between the neutron dose (dn ) and gamma dose 
(dy), before and after the fast (63N i) and slow (36C I) neutron activation measurement 
corrections were made to the neutron dose estimates, shown in Figure 2. This 
relationship was then used to replace the percentage of the mIssIng values that 
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corresponds to survivors whose doses were set equal to zero (the cohort also included an 
essentially unexposed group sample beyond 3 km) (Pierce and Preston 2000). 
RESULTS: 
Solid Cancer 
In Table 1, the RBE values are calculated for the corrected (adjusted for dose 
uncertainty and error in the neutron doses) and uncorrected doses and given as an average 
for each dose group. A ratio of the average dose, with a variable RBE to those with a 
constant RBE of 10, are given to illustrate the effect of the variable RBE on the total 
weighted dose, where the weighted dose is calculated as dy + RBE(dy,dn}dn . The effect 
of a variable RBE is an increase in the estimated doses for doses originally less than one 
Sv and a decrease in the dose estimates for those greater than 1 Sv. This finding is more 
dramatic for the low dose groups once the adjustments for uncertainty and error have 
been incorporated. 
Table 1 - Estimated average RBE values and ratio of the variable RBE dose to the fixed RBE (=10) dose 
for weighted dose groups using the corrected and uncorrected doses 
Weighted Dose 1Svl < 0.10 0.10-0.25 0.25-0.50 0.50-1.0 1.0-1.5 1.5-2.0 
RBE 46.0 27.6 17.4 10.0 6.1 4.6 
Uncorrected Dose RBE(Var) 
1.07 1.07 1.03 1.00 0.97 0.95 
Dose RBE(lO) 
RBE 45.2 26.5 16.9 10.1 6.3 4.7 
Corrected Dose RBE(Var} 
1.46 1.25 1.12 1.03 0.96 0.94 
Dose RBE(lO) 
In the original analysis of solid cancer incidence by Thompson et al. (1994), the 
data were adjusted for city, sex, age-at-exposure, and calendar time, with the excess 
relative risk assumed to be linear in dose and modified by sex and age-at-exposure. The 
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sex, year of birth, log age, and log age squared. Hoel and Li (1998) observed that the 
fitted dose response curve underestimates the number of cancers in the zero dose group 
while overestimating the lowest exposure group (0.01 to 0.1 Sv), as one would expect in 
the case of low dose non-linearities. These calculations suggest the possibility of non-
linearities in the low dose region of the dose response curve; therefore, a dose response 
curve that incorporates a linear threshold term was fit to the solid incidence data. In 
Figure 3, the change in deviance score from the linear no threshold model versus the 
model's threshold dose are plotted. Three types of dose values are considered: the 
uncorrected original dose, doses corrected for uncertainty and error with a fixed RBE 
value, and corrected doses with a dose dependent RBE. We observe that with 
uncorrected doses and fixed corrected doses, a threshold up to 0.1 Sv appears to improve 
in the models fit, although there is no significant difference between the linear and 
threshold models. In the case of the variable corrected dose, the threshold provides a 
significant improvement in the fit of the model at doses between 0.07 Sv and 0.17 Sv. 
Models of solid tumor mortality give a different picture. In the paper by Pierce et 
al. (1996), cancer mortality is modeled using a stratified background and an excess 
relative risk that is linear in dose and dependent on sex and age-at-exposure. We see that 
the addition of a threshold tenn offers no improvement in the fit of the model, but 
threshold doses up to 0.15 Sv are not statistically worse from the no threshold model, 
shown in Figure 4, where the change in deviance is plotted for the three different dose 
estimates as a function of the threshold dose. 
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Leukemia 
Data on leukemia incidence from Preston et al. (1994) was used to examine the 
dose response curve for total leukemias. At doses less than 0.30 Sv the linear no 
threshold model based on the doses available in the RERF data, overestimate the risk of 
leukemia predicted from the corrected doses and threshold models. A threshold term was 
incorporated into the models as was done with solid tumors. Figure 5 shows the change 
in the fitted deviance values plotted versus the threshold doses used in the model. In the 
cases of leukemias, we see an improvement in the fit of the model with the addition of a 
threshold. The threshold model provides a statistically better description of the data than 
is seen with the no threshold model for threshold values up to 0.15 Sv with the 
uncorrected doses and fixed corrected doses and up to 0.2 Sv for the variable corrected 
doses. The results of adding a threshold for the subtypes leukemia were similar to the 
results for the uncorrected doses presented in Hoel and Li (1998). ALL and CML were fit 
with a dose response function linear in dose while AML as was total leukemia were fit 
with a linear-quadratic function. For CML the threshold model provided a significantly 
better description of the data than the no-threshold model, while the addition of a 
threshold for ALL and AML indicated an improvement in fit that was not statistically 
better than the no-threshold model. The original, uncorrected doses, as well as, the 
corrected doses have been fit with a linear-quadratic dose function as shown in Figure 6. 
We see that the effect of the dose corrections indicate a noticeable difference in the risk 
estimates even in the low dose region of the curve. 
The leukemia mortality data comes from the same paper as the solid tumor 
mortality by Pierce et al. (1996), but the leukemia models are more complicated. 
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Leukemia mortality is modeled uSIng a parametrically modeled background and an 
excess additive risk component that is linear-quadratic in dose and modified by sex, age-
at-exposure, and time since exposure. The change in the fitted deviance values is plotted 
against the threshold doses for leukemia mortality in Figure 7. Although we see an 
improvement in the fit of the model with a threshold, similar to the leukemia incidence 
models, the improvement is not significant with the leukemia mortality data. 
DISCUSSION: 
Theses analyses have shown that the A-bomb survivor data for radiation-induced 
cancers (solid tumors and leukemias) are consistent with a non-linear dose response 
model. These findings have been seen with the current dosimetry, as well as with the 
doses that incorporate information about the uncertainty in the dose estimates, a 
correction for the systematic error in the neutron estimates, and the incorporation of a 
RBE value that corresponds with current radiobiological knowledge. The estimated 
threshold levels depend on the dose estimates that are used. For solid tumor incidence, 
the incorporation of the uncertainty and error corrections indicate a more pronounced 
improvement in the fit. Furthennore, when the variable RBE was added, the threshold 
model became significantly better with an optimal threshold value between 0.10 and 0.15 
Sv-in the case of leukemia incidence, the results were the opposite. The uncorrected 
dose resulted in the most significant improvement with a threshold of about 0.1 Sv, the 
fixed corrected doses was less significant but with approximately the same threshold, and 
the variable corrected doses resulted the least significant improvement but with a 
threshold of about 0.17 Sv. The results from Little and Muirhead (2000) which used a 
fixed REE of 20 while correcting for uncertainty in the dose estimates and bringing the 
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neutron estimates in line with the slow neutron activation measurements indicated similar 
findings to the results in this paper when the RBE is fixed. The solid tumors incidence 
data suggests an appreciable upward curvature, although not statistically significant, 
while the leukemia incidence data indicated a reduction in the significance of the 
curvature. In these analyses with a fixed RBE, the threshold becomes more significant 
for solid tumor incidence, although it does not reach statistical significance; while the 
threshold model for the leukemia data remains statistically significant, the significance of 
the threshold is reduced. 
Multiple imputation (Rubin 1987) 1S a popular statistical method used with 
missing data or data measured with error, we applied multiple imputation methods to 
impute the true dose given the nominal dose for the solid tumor incidence data. A 
lognonnal model was used to impute the true dose given the nominal dose, and 50 
multiple imputation datasets were performed. The multiple imputation estimates and 
standard error estimates were very similar to those obtained using the corrected doses. In 
-
particular, using multiple imputation, Pdose = 1.198 (estimated standard error 0.3721); 
using the corrected doses, Pdose== 1.186 (estimated standard error 0.3676). Thus, the 
similarity of the estimates from these two methods suggests that using the corrected doses 
will produce unbiased estimates. 
The cancer mortality data did not indicate an improvement with the addition of a 
threshold and appears to be inconsistent with the observation of non-linearity in the low 
dose region of the dose response curve, even with adjustments for the suggested errors in 
the doses. This could be due to a bias introduced due to urban-rural differences. Pierce 
and Preston (2000) observed that the distal group (more than 3000 meters from the 
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hypocenter) has about a 5% higher cancer mortality rate than estimated for the zero dose 
group from the proximal survivors. Although the bias is small, it can substantially affect 
the assessment of risk at low doses. 
Other studies have been used to assess the effects of low dose radiation in the 
production of cancers. A study of cancer mortality in a cohort of Canadian Fluoroscopy 
patients, fractionated exposures to low LET radiation resulted in a decreased lung cancer 
mortality than would be expected at the same dose from the A-bomb data (Howe 1995), 
while the risk of breast cancer mortality was not effected by fractionation (Howe and 
McLaughlin 1996). Experimental animal studies have also provided information 
regarding the effect of dose rate on the induction of cancers and have resulted in the 
recommendation of a dose rate effectiveness factor (DREF) between 2 and 10 for low 
doses of low LET radiation (Committee on the Biological Effects of Ionizing Radiation 
1990). If the effectiveness of radiation is reduced when the exposures are protracted, the 
result could be an effect of non-linearity at low doses. 
Occupational studies of radiation workers have also provided infonnation on the 
issue of linearity at low doses. However, when total doses are low, occupational data do 
not provide clear evidence of risk because the precision of these studies is limited by the 
data and with small exposures, there is the possibility of masking the radiation effect with 
the "healthy worker effect" that is often associated with occupational studies (Cardis et 
al. 2001). The curvelinear dose response relationship found for leukemia in the A-bomb 
data indicates no noticeable risk at doses below 0.20 Sv. Most occupational studies with 
low cumulative doses have also shown no excess risk of leukemia at low doses, although 
there are some exceptions (National Council on Radiation Protection and Measurements 
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2001\. although studies have shown that excess risks of leukemia in occupational studies 
are usually associated with dose greater than 0.4 Sv. The problem with these studies, as 
with most epidemiological studies of radiation exposure is that they suffer limitations, 
which impact the interpretation of the data and may make the capability of resolving the 
issue of low dose risk beyond the capability of epidemiological data alone. 
The scientific basis for the no threshold model comes from scientific studies of 
mutagenesis, clastogenic, and chromosomal aberrations. Mutation frequencies have 
been shown to increase with either linear or linear-quadratic dose response curves, 
depending on the radiation quality, LET of the radiation, dose rate, and genetic 
background of the cell. In either case, there is no direct evidence of a threshold; 
therefore, if cancer fonnation is directly related to mutation induction the data does not 
support a threshold in the cancer dose response, but cannot rule out, a nonlinear dose 
response. Chromosomal studies can only lead to predictions of a threshold if DNA repair 
is error free at low doses, but the existing data cannot support or refute these predictions. 
Although a linear no threshold model fits cellular data for many biological alterations that 
may be precursors for cancer, as well as the epidemiological data, it is important to note 
that they do not provide evidence that low dose non-linearities or threshold are absent in 
the data. Further, the discovery of issues such as genomic and chromosomal instability, 
bystander effects, and adaptive response are currently changing the understanding of 
radiobiology, and must now be examined to see what effects they have at low doses. 
CONCLUSION: 
The maIn conclusion that can be made from these analyses is that even after 
adjustments are made for uncertainty associated with the dose estimates, systematic error 
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in the neutron estimates and a dose-dependent RBE a threshold like dose response is still 
consistent with the A-bomb cancer and leukemia incidence data, reinforcing the findings 
of Hoel and Li (1998) who found similar results using the uncorrected original doses. 
And although a linear no threshold model fits the data it does not provide evidence 
against low-dose non-linearities or threshold models. The shape of the dose response 
low-dose is an important issue in radiation protection that cannot be resolved with 
statistics and epidemiology; it will require a better understanding of the radiation biology 
at low doses and the effects on radiation carcinogenesis. 
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Figure 1 - The ratio of the neutron absorbed dose to the gamma absorbed dose versus the absorbed gamma dose. The doses 
used are average organ doses, which are equivalent to the marrow doses CKellerer 2001). The current dosimetry, the DS86 is 
given as (-); the estimates based on the thermal neutron activation measurements represented by C····) (Straume 1992); (---) 
represents the estimates based on an intermediate adjustment that is consistent with the available 63Ni measurements from 
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Figure2: The mean neutron doses versus the mean gamma ray doses to the colon in the RERF datasets for cancer mortality and incidence 
(Hiroshima). The solid line represents the uncorrected doses that are available in the data, the dotted line (---) represents the correction for the 
slow neutrons combined with the uncertainty correction while the dashed line (- -) represents the fast neutron correction combined with the 
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Figure 3 - Plot of the change in statistical deviance from a no threshold model versus the model's threshold value are given for solid tumor 
incidence. The smaller the deviance value the better the models statistical fit to the data - therefore, the large negative changes in deviance 
indicate that the threshold model fits the data better than a no threshold model. The horizontal line indicates when the change in deviance is 
significantly better (p=O .05) than a no threshold model. D lOis the uncorrected colon dose estimates available in the solid tumor incidence 
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Figure 4 - Plots of the change in deviance versus threshold dose similar to Figure 1 for solid tumor mortality. AIO is the adjusted colon 
dose with a fixed RBE of 10 that is given in the mortality data, D 1 ON is the fixed corrected dose estimates) and DVN is the variable 
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Figure 5 - Plots of the change in deviance versus threshold dose similar to Figure 1 for leukemia incidence data. D lOis the uncorrected 
marrow dose with a fixed RBE of 10 that is given in the leukemia incidence data, DION is the fixed corrected dose estimates, and DVN 





























-- Corrected Dose (no threshold) 
- - Corrected Dose (threhsold) 
-- Uncorrected Dose (no threshold) 
- - - Uncorrected Dose (threshold) 
0.5 1.0 1.5 2.0 
Total Dose (Sv) 
-- Corrected Dose (no threshold) 
- - Corrected Dose (threhsold) 
-- Uncorrected Dose (no threshold) 
- - - Uncorrected Dose (threshold) 








0.00 0.25 0.50 0.75 1.00 
Total Dose (Sv) 
Figure 6 - Dose response curve for leukemia incidence in Hiroshima. Plot of the excess 
absolute risk of leukemia as a function of dose for males that were 20-39 year old at the time 
of bombing, 10 years after the exposure. The lower figure depicts the effects of the different 
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Figure 7 - Plots of the change in deviance versus threshold dose similar to Figure 1 for leukemia mortality. AIO is the adjusted marrow 
dose with a fixed REE of 10 that is given in the mortality data, D 1 ON is the fixed corrected dose estimates, and DVN is the variable 
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ABSTRACT: 
A low dose subset of experimental mortality data from experiments conducted at 
the Argonne National Laboratory on the effects of exposure of B6CF) mice to whole-
body irradiation, gamma rays « 300cGy) or fission neutrons « 30cGy), were analyzed 
to assess the shape of the dose response and the effects of fractionation. The Cox 
proportional hazards model was used as an empirical model, while the two-stage clonal 
expansion model was used as the biologically based cancer model in which information 
on the carcinogenesis process is incorporated into the model. The two models resulted in 
similar descriptions of the dose response curves, cancer risks, neutron relative biological 
effectiveness and dose rate effectiveness factor associated with exposure to ionizing 
radiation. Both models suggest that a dose-response curve linear in dose provides an 
adequate fit to the data. Fractionation reduced the effectiveness of gamma radiation 
while had no noticeable impact on the effectiveness of neutron exposure. 
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INTRODUCTION: 
Many late effects from exposure to ionizing radiation, including cancers, have 
been described in the literature. The identification and quantification of radiation-induced 
health effects is an important and complex issue. The recommendations for radiation 
safety and protection from the International Commission on Radiological Protection 
(ICRP) are made based on the risk estimates for late effects from low dose radiation 
(ICRP 1991). A major obstacle in this process is the limited availability of data to 
directly measure the health effects of radiation on human populations. The problem is 
further hampered because the data on human exposures do not include the energy 
spectrum and patterns of exposure that are most relevant. One way to circumvent this 
problem is to use experimental data from laboratory animals and extrapolate across 
species to man (Carnes et al. 1998). 
Another issue to consider is that there are many models available to generate risk 
estimates. Some models are empirical, purely mathematical and driven by the data, 
while others are mechanistic; attempt to incorporate biological plausibility within the 
mathematics. Both categories of models have a history in radiation biology and different 
issues that related to them. The Cox proportional hazards model is an empirical model 
that uses time to event as well as covariate data to describe the data, without considering 
what is happening biologically. A parametric for of the covariate effect is assumed, 
while the baseline hazard rate is treat nonparametrically allowing inferences to be made 
about the covariate effect, but not the baseline hazard. The two-stage clonal expansion 
model, also referred to as the Moolgavkar-Venzon-Knudson model (MVK model), is a 
biologically based cancer model that accounts for clonal expansion, replication, 
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differentiation, and mutation of the cells in the first altered state (initiated cells) as well as 
the mutation rates of nonnal cells. Questions as to whether or not non-linearities exists at 
low doses in the dose-response add to the issue and debate over which model should be 
used when investigating low dose effects (Hoel and Li 1998). 
The two-stage clonal expansion model has been applied to data on radiation-
induced cancers in humans and rats as well as other environmental cancers. The A-bomb 
survivors data indicated an initiation effect, but contained no information on promotion 
(Kai et al. 1997). In studies of Colorado uranium miners exposed to radon (Luebeck et al. 
1999) and radon exposed rats (Heidemeich et al. 2000) a promotion effect was necessary 
to describe the data. 
The two-stage clonal expansion model assumes that at any given time there are a 
large constant number of somatic cells susceptible to genetic transformation (Xo), since 







Figure 1: The two-stage clonal expansion model where J-li is the mutation rate of normal cells (per unit 
time); f..l2 is the mutation rate of initiated cells (per unit time per cell); J3 is the birth I replication rate of 
initiated cells (per unit time per cell); and 8 is the death I differentiation rate of initiated cells (per unit time 
per cell). 
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is constant through the observation. Initiated cells, resulting from a somatic mutation 
(Xt(t)) reproduce in a stochastic manner, and once a malignant cell (X2(t)) is formed by a 
second mutation, it will inevitably become an observable tumor (Moolgavkar 1986; 
Heidenreich et al. 1997b). 
The model consists of four time-independent parameters J.lI, ~, b, and J.l2 described 
in Figure 1. Each normal cell has a non-zero probability of undergoing a transformation 
into an initiated cell, at a rate of v per unit time per cell, so that J.11 (= vXo) is a constant 
transition rate per unit time. Each initiated cell may undergo three events; they can 
replicate into two intermediate cells at a rate rJ per unit time per cell, die at a rate of 8 per 
unit time per cell, or divide into one malignant cell and one initiated cell at a rate of Jl-2 
per unit time per cell. 
There is a lack of identifiability because not all four of these parameters can be 
determined from tumor incidence data (Hanin and Yakovlev 1996), therefore, it is only 
possible to calculate three unique estimates for the parameters. In order to solve the 
system of equations, the parameter space must be reduced either by introducing 
additional data, reparameterizing the parameter space, or placing a restriction on the 
existing parameters. In this paper, the parameter space is reduced by reparameterizing 
into three distinct combinations of the original parameters: (I.) 'V = J3 - (5 - Jl2 ' (2.) 
P = J.11 Jl 2 , and (3.) 11 = Jll and setting the differentiation rate equal to zero (8==0). 
~ 
The two-stage model can be described in terms of initiation, promotion and 
progression (or transformation). Increasing the probability of a normal cell undergoing a 
transfonnation into an initiated cell is referred to as initiation. Promotion is the increase 
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in the number of initiated cells through clonal growth (increasing the difference between 
the replication rate «(3) and the differentiation rate (6)). The transformation from an 
intermediate cell to a malignant cell is referred to as progression. Detennining which of 
the stage or stages in the model are affected by radiation, will in tum, help describes the 
modifying effect of fractionation. 
The objective in this paper is to compare the Cox proportional hazards model with 
the two-stage clonal expansion model, to see how well they fit the data and what the say 
about the cancer dose effect of radiation. In doing this we look at what each model 
estimates for the relative biological effectiveness of neutron, and the dose rate 
effectiveness factor associated with low dose rates of radiation and how these relate to 
values used in radiation protection. 
MATERIAL AND METHODS: 
Data 
The JANUS program at the Biological and Medical Research Division of 
Argonne National Laboratory (ANL) compiled a database between 1970 and 1992 on the 
response of Fl hybrid mice; the B6CF1 (a cross between C57BL/6 x BALB/c mice), to 
external whole body irradiation. Detailed information concerning the individual 
experiment designs, the animals care and maintenance and radiation factors have been 
published previously (Grahn et al. 1992,1995). 
The data include a total of between 20,000 and 40,000 mice, depending on the 
level of pathology. The mice were either controls or exposed to 60CO y rays or fission 
neutrons (mean energy 0.85 MeV) over a range ofpredetennined total doses calculated in 
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centigrays (cGy) at the midline of the mouse. The three basic patterns of exposure 
investigated were: single exposure, 24 once-weekly exposures, and 60 once-weekly 
exposures. The average age at onset of exposure was 110 days, in order to study the 
biological consequences of occupational levels of exposure to radiation on young adult 
animals. The mice were followed for the duration of their natural lives, at which point 
pathology judgments based on macroscopic examinations (autopsy) were used to 
determine the cause of death, as well a subset of these animals were selected at random to 
undergo a histological examination (microscopic) (Grahn et al. 1992). Comparisons of 
the macroscopic and microscopic pathology records for primary tumors causing or 
contributing to death are in agreement 980/0 of the time (Grahn et al. 1995). This suggests 
that the macroscopic data, with its larger sample size, can be used reliably for the analysis 
of these endpoints (Grahn et aL 1992). 
For the analyses in this paper, we are only interested in a subset of the JANUS 
data (Table 1) to examine lowest available doses of gamma and neutron exposures and 
the effects of fractionating the exposure. Therefore, the data has been restricted to mice 
receiving total doses less than 300 cGy gamma ray exposures and 30 cGy for neutrons. 
This restriction resulted in the exclusion of the 24 once-weekly data because of the lack 
of comparable doses in this dose range. This subset of the data was the basis of the 
recent analysis reported by Carnes et al. (2002) 
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Table 1: Summary of the Mice - Exposure Patterns, Radiation Doses, Sample Sizes, and Mean Ages at 
Death 
Exposure Dose * MAD** 
Number 
of Mice 
0 987 191 
Single Exposure 86 976 189 
Gamma 137 947 150 
198 923 308 
0 998 558 
60 Once-Weekly 100 980 562 
Gamma 200 967 164 
300 924 76 
0 981 1026 
1 988 661 
Single Exposure 2 973 411 
Neutrons 5 949 312 
9 932 230 
19 921 183 
0 997 534 
2 987 520 
60 Once-Weekly 
8 975 204 Neutrons 
14 924 219 
22 913 225 
* Dose - total accumulated dose measured in centigrey (cGy) 























On average, the control mice and the mice with lower exposure doses lived longer 
than the mice exposed to higher irradiation doses (see Table 1). Therefore, for the 
purpose of comparing the different exposure patterns and dose groups, it is necessary to 
truncate the populations at a point in time when there are still some mice alive in all of 
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the exposure groups. For these analyses, the data is truncated at 3 years (1095 days) from 
the date of first exposure, with any tumors occurring after this date treated as censored. 
Dose-response analyses were perfonned to examine the shape of the dose-
response function in the low dose region for each exposure pattern. Primary tumor, 
defined as all tumors that detennined to have caused or contributed to the death of the 
mouse, is the endpoint of interest in this study. The results were generated using three 
different models: 
(1.) The Cox proportional hazard model (Cox 1972); 
A(t I D) = Ao(t)exp[~'D], [1] 
where t, the time variable, is the days at risk, D is a function of the total accumulated 
dose treated as a continuous variable, A(t I D) is the hazard function at time t given dose 
D for a mouse, Ao(t) is the unspecified baseline hazard function, and exp[I3'D] is the 
relative risk. 
To determine the form of dose to be used in the final model three forms of dose 
were considered. 
Linear dose D = dose 
Linear-Quadratic dose [
dOse] 
D = dose 2 , and [2] 
Log-Linear dose o = log(dose) . 
Each fonn of dose was modeled for each exposure pattern to detennine how well they 
described the data. The Akaike selection criterion (Akaike 1976) was used to evaluate 
the least squares fitting to the models and determine which was the most appropriate 
function of dose to use in the model. 
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(2.) The piecewise linear Cox model is used to examine the possibility of non-
linearity in the low dose region of the dose response curve that would be missed by use of 
the linear Cox proportional hazards model (Nakamura et al. 1999). This model uses the 
basic Cox proportional hazards model described above, with the relative risk defined as a 
linear combination of the original covariate (dose), and a function of the intermediate 
dose cut points such as the following model for single gamma exposure, 
A(t I D) = A.o(t)exp[~oD + P1D86 + f32D137] . [3] 
Table 2 lists the possible dose cut points to be investigated in this analysis for each of the 
exposure patterns of gamma and neutron. Stepwise Cox regression methods are used to 
detennine which dose cut points, if any, are significant and therefore should be included 
in the model. 
Table 2: Definition of piecewise linear functions. 
Single Exposure 60 Once-Weekly Exposure 
Gamma Neutron Gamma Neutron 
D86 =max{O, D-86} 01 =max{O, 0-1} D1 OO=max{O, D-1 ~O} 02 =max{O,0-2} 
·D137=max{O,D-137} D2=max{O,D-2} 0200=max{O,D-200} D8 =max{O, D-8} 
D5=max{O,D-5} D14=max{O,D-14} 
D9=max{O,D-9} 
(3.) In the two-stage clonal expansion model, since the parameters (8) take on 
only positive values they are modeled in the log-linear form so that 
log(9) = a + b D , [4] 
where D is the total accumulated gamma or neutron dose given to the mouse, a is a 
constant term, and b is the regression coefficient. The maximum likelihood estimates 
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(MLE) of the parameters are estimated for the conditional likelihood function using a 
simple transformation of the chain rule. Next, these values are converted into the original 
parameter values. More details on the method are available in the appendix; and a 
detailed comparison of the conditional and the original likelihood is dealt with in 
Nakamura and Hoel (unpublished paper). 
To graphically examine and compare the result of the cumulative hazard estimates 
from the models discussed above, Kaplan-Meier estimates (K-M) of the observed hazard 
were also calculated for each exposure pattern and dose group as a reference. 
RESULTS: 
The results of evaluating the possible forms of dose in the Cox proportional 
hazards model are shown in Table 3. The model was evaluated individually for each 
exposure pattern; and in all cases, the Akaike information criterion (AIC) was smallest 
for the linear form of dose, indicating that the linear model was the best fit or was 
indistinguishable from the other forms of the model. This finding is consistent with 
previous life shortening studies that found the dose-response curve to be linear for 
neutrons less than 10-50 cGy (depending on the dose-rate) and for the entire range of 
gamma irradiation (Storer and Fry 1995;Cames et al. 1989;Thomson and Grahn 
1988;Thomson et al. 1985). Subsequent references to the Cox proportional hazards 
model will be in reference to the linear fonn of the model. 
- 65 -
6.2 Comparison of Two Models of Risk Estimation: Part I 
Table 3: Akaike Information Criterion Scores for the various forms of dose explored In the Cox 
proportional hazards model for each exposure pattern. 
Radiation Exposure Ale Score 
ft 
Quality Pattern Linear Linear-Quadratic Log-Linear 
Gamma Single 7799.714 7799.824 7806.817 
Fractionated 15036~837 15038.815 15038.152 
Neutron 
Single 29724.033 29725.728 29727.800 
Fractionated 18426.803 18428.603 18430.238 
* The smallest Ale Score represent the form of the model that best fits the data and is represented 
in bold face. 
The results for our examination of possible non-linearity using the piecewise 
linear model are given in table 4. For three of the four exposure patterns (all except the 
fractionated gamma exposure), the selection process for the piece-wise linear model 
found a threshold dose to be more significant than the simple linear dose. In these cases, 
the estimated deviance for the threshold model and the linear non-threshold model were 
used to test whether or not the threshold significantly improved the fit of the model. For 
all exposure patterns, the results indicate that the piece-wise linear model did not fit the 
data better than the linear model: single exposure of gamma (p=O.18), neutron (p=O.67), 
and fractionated neutron exposure (p=O.62). 
Table 4 - Comparison of the linear model to that of the piece-wise linear model for each of the exposure 
patterns. 
Radiation Exposure Pattern Significant Cut p-value 
Quality Points * 
Gamma Single 0137 0.18 
Fractionated Dose 1.00 
Neutron 
Single 01 0.67 
Fractionated 02 0.62 
* Significant cut points are from Table 2 
- 66-
6.2 Comparison of Two Models of Risk Estimation: Part I 
Radiation can affect the initiation rate, promotion rate, progression rate, or a 
combination of these three rates. Therefore, there are seven different forms of the model 
that must be considered - those in which only a single stage is affected, those in which 
two of the stages are affected, and the model in which all three stages are affected by 
radiation. To determine which of the parameters were affected, we calculated the log 
likelihood for each of the models. For this data, we determined that the best model to 
describe all of the exposure patterns is the one in which J..LI is the only parameter directly 
affected by dose. Although, for most exposures the other parameters did not behave 
significantly worse, the J..Ll model was consistently the better model. The slope 
coefficient of 109(J..ll) is positive for all exposure patterns (Table 5), indicating an increase 
in the mutation rate with increasing dose. 
Table 5 - Parameter estimates from the two-stage clonal expansion model 
Exposure log(J,11) 10g«(3) IOg(J!2) 
a* b a b a b 
Gamma Single -4.8491 0.001991 -4.8342 -- -12.1220 --
Gamma Fractionated -4.6357 0.001557 -4.7610 -- -12.6930 --
Neutron Single -4.5690 0.023354 -4.8943 -- -12.2242 --
Neutron Fractionated -4.7732 0.023936 -4.7040 -- -12.8462 --
* Each parameter is modeled as logeS) = a + bD. (--) value for a parameter indicates that that parameter 
was not included in the model. 
Shown in Figure 2 are the estimated log cumulative hazard rates plotted as a 
function of time (days at risk), to compare how well the two-stage model (-) and the 
Cox proportional hazards model (---) fit with the Kaplan-Meier (- step) observed hazard 
estimates. The two-stage model is a function of time as a continuous variable (see 
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appendix); therefore, its result is a smooth line, where the Cox proportional hazards 
model uses individual event times in the model, resulting in a step function. Each figure 
illustrates the results for the control mice (dose group = 0) as well as a higher dose group; 
the higher dose groups were chosen to be comparable within each radiation type. 
For all exposure groups, both models give a similar fit to the observed values 
(Kaplan-Meier) after approximately 600 DAR (days since first exposure). Prior to this 
time, the number of observed events is small and the resulting Kaplan-Meier estimates 
have large confidence intervals. The difference between the curves for the two dose 
groups represents the effect of the increase in dose. In Figure 2B, we see that for the 
same dose there is a noticeably reduced effect for the fractionated gamma exposure 
compared to the single gamma exposure in Figure 2A. When comparing the neutron 
exposures (Figures 2C and 2D), there is no visible difference in the effectiveness between 
the two exposure groups. 
The dose-response curves are shown in Figure 3. The Cox proportional hazards 
(-) and the two-stage clonal expansion model ( ---) are plotted with the observed Kaplan-
Meier hazards and the 95% confidence intervals for each dose group as a reference. The 
two-stage model estimates the absolute risk for each dose group; consequently, the points 
of the curve are fixed, while the Cox proportional hazards model results in estimates of 
relative risk. Therefore, to facilitate comparison, without changing the meaning or 
estimated risk, the estimated risk of the control group for the Cox model is set equal to 
that of the two-stage model. 
We see, in Figure 3, that the two models predict very similar results for all 
exposure patterns. Since the dose response curve for all models is linear in the dose 
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range of this analysis, the main noticeable difference in the two models is the slope of the 
curves. Once again we can see graphically that the fractionated gamma exposure results 
in a reduction of the slope of the dose-response curve, indicating a decrease in the 
effectiveness, while there is no noticeable change in the slope for the neutron exposure. 
Dose Rate and RBE 
There are two measures that are used in the literature to describe the effects of 
different radiation quality and dose-rates: relative biological effectiveness (RBE) and 
dose rate effectiveness factor (DREF). The RBE, as defined in BEIR V, is the biological 
potency of one radiation as compared with another to produce the same biological 
endpoint. The DREF is a factor by which the effect caused by a specific dose of radiation 
changes at low compared to high dose rates (Committee on the Biological Effects of 
Ionizing Radiation 1990). The DREF used is similar to the dose and dose rate 
effectiveness factor (DDREF) used by ICRP (ICRP 1991) and UNSCEAR (United 
Nations Scientific Committee on the Effects of Atomic Radiation 1994) when it is 
assumed that at low doses the cancer effect is linear in dose. 
It is well established in the literature that high-LET radiations have greater 
biological effectiveness than low-LET radiations (Balcer-Kubiczek et al. 1994;Brenner 
and Hall 1992). The problem is that the evidence suggests that there is no one RBE value 
for neutrons, because the RBE value is dependent on the dose, dose-rate, energy, 
fractionation, target tissue, and time (Carnes and Grahn 1991). The neutron relative 
biological effectiveness is calculated as the ratio of the linear slope coefficients of the 
neutron and the reference radiation (ICRU 1986), in this study 60CO gamma. 
[5] 
- 69-
6.2 Comparison of Two Models of Risk Estimation: Part I 
with SE(RBE) ==_1 
a y 
where a ~ and a ~ are the variance estimates of the slope coefficients. F or single 
exposure, the RBE estimates are 12.46 (+ 4.4) and 11.73(+ 4.0) for the Cox proportional 
hazards model and the two-stage models respectively, while the estimates for fractionated 
exposures are 19.67 (+ 6.2) and 20.69 (+ 5.9). The increase in the RBE for fractionated 
exposures is due mostly (about 800/0) to the reduced effectiveness of gamma at the lower 
dose-rates. 
To compare the effectiveness of different dose rates for equal doses, dose rate 
effectiveness factor (DREF) is used as described above. To estimate the DREF, we fit 
data obtained at high and low dose rates separately (single and fractionated exposure) and 
used the estimated slope coefficients to calculate the DREF as 
with 
where 
SE(DREF)u = as 
a f -c 
and SE(DREF)L = as 
a f +c 
[6] 
The DREF for gamma irradiation is 1.51 (L=1.03 and U=2.4S) for the Cox model versus 
1.72 for the two-stage model; while for the neutron exposure, the DREFs are 0.94 
(L=O.73 and U=I.22) and 0.99 for the Cox model and two-stage model respectively. The 
values are not different than unity; and therefore, indicate that the dose rate of the neutron 
exposure at lower doses does not change its effectiveness. 
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Table 6 presents the relative risk estimates for each exposure pattern and model, 
with the estimates calculated for total accumulated doses of 100 cOy gamma exposure 
and 10 cGy neutron exposure. The results indicate that the choice of model does not 
affect the estimates of risk. Although, they do suggest a reduction in the effectiveness of 
the gamma exposure with fractionation while the fractionation of neutron exposures 
indicate no change in effectiveness. 
Table 6 - Excess Relative Risk estimates for 100 cGy gamma or 10 cGy neutron radiation exposure for the 
Cox proportional hazards model and the two-stage model 
Radiation Exposure Cox Model Two-Stage Model 
Gamma Single 1.20 1.22 
Fractionated 1.13 1.12 
Neutron 
Single 1.26 1.26 
Fractionated 1.28 1.27 
DISCUSSION: 
We performed our analysis on mice exposed to single or fractionated doses of 
fission neutron or 60CO gamma rays in an arbitrarily selected low dose region (less than 
30 cGy neutron and 300 cGy gamma) of the available data, the same subset mice used in 
Carnes et al. (2002) analysis of non-cancer morbidity. The data for neutron exposure 
had doses ranging from 0-22 cGy, without any major gaps in the lower doses of the data, 
which can therefore accurately describe the low dose region, but the data for gamma 
exposure was much more limited, with the smallest doses being 86 cOy for single 
exposure and 100 cGy for fractionated exposure. The piecewise linear model and the 
Kaplan-Meier (K-M) estimates indicate that there may be some [onn of non-linearity in 
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the low dose region of the acute gamma exposure. However, the confidence interval of 
the K-M estimate was large; and without data for doses between 0 and 86 cGy, it is 
impossible to discern it from a linear model. This unfortunate gap in the data affects our 
ability to definitively address the issue of linearity in the low dose region of the gamma 
dose-response curve. 
The endpoint of interest in this paper, primary tumors, can be broken down into 
two subcomponents - lymphoreticular tumors (all leukemia and lymphomas) and solid 
tumors (all cancer except lymphoreticular tumors). At low doses, all the models for these 
subcomponents were similar to that for primary tumor for all exposure patterns_ The 
linear Cox model and the J-ll two-stage model were the best fits; so the only variation was 
in the slope estimates for the exposure patterns except for single neutron exposure, which 
indicated no dose dependence for lymphoreticular tumors at low doses. 
The RBEs estimated in this analysis are strictly for comparing the two models and 
are not reliable estimates, because in order to have doses and dose ranges that were 
comparable between the acute and fractionated exposure, we were forced by gaps in the 
data to select female mice for the neutron exposure and male mice for the gamma 
exposure. We see that since the estimated RBEs are based on the slopes estimate and the 
two models resulted in similar slope estimates, the two models give similar results for 
RBE (11_73 - 20.69 depending on fractionation)_ It is interesting to note, that although 
these estimates are not reliable, they agree well with earlier sex dependent estimates of 
the REE for life shortening studies (Thomson and Grahn 1 988;Storer and Mitchell 1984). 
The neutron RBEs resulting from the different studies have ranged from 2 to 100 
depending on the dose, dose-rate, cell or tissue type being examined, and cancer endpoint 
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being examined. The majority of the analyses of the atomic bomb data use an RBE value 
of either 10 or 20, these being consistent with the quality factor "Q" of 20 recommended 
by national and international groups on radiation protection (Committee on the Biological 
Effects of Ionizing Radiation 1990;ICRP 1991). 
The reduced effectiveness of gamma radiation seen by both models (DREF = 1.5 
and 1.7) has been reported in many studies including previous analyses for the endpoint 
of life shortening in the JANUS data. Although an increase in the effectiveness of 
neutron exposure with protracted doses has been reported, it is not seen until higher doses 
(greater than 40 cGy); and therefore, was not expected to be seen in this analysis (Carnes 
et al. 1989). 
In the two-stage model, the results appear linear for all combinations of dose-
dependent parameters in the low dose range investigated. When initiation is the only 
stage affected by radiation exposure (J.ll parameter), the dose response curve is linear 
over all doses with the slope equal to the regression coefficient of the dose term ( b) in 
equation 4. The results of the other models appear linear in the dose range examined, 
although they are actually non-linear; this non-linearity becomes more evident at higher 
doses. 
It is interesting to note that at low doses, the estimated risk from the two-stage 
model was not affected by which combination of dose-dependent parameters was used. 
Therefore, the decision to use the fJ.l model did not have an affect on the resulting risk 
estimates. In deciding to use the mutation rate model for all exposure groups, we 
investigated the net proliferation model for the 60 once-weekly neutron exposure because 
it provided a similar fit to the data, but was much more difficult to interpret in tenns of 
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radiation carcinogenesis. Although the results of the two models are very similar in their 
risk estimates, their biological interpretations are quite different. It has been generally 
accepted that most of the biological consequences of ionizing radiation are due to the 
interaction with the DNA producing changes in the replication and repair (UNSCEAR 
2000). These changes are know to take place immediately following exposure and can 
affect the initiation mechanism. The mechanism of promotion is an increase in the growth 
imbalance during the time of exposure. This would mean that the radiation would induce 
a rapid increase in the replication rate ([3) or decrease in the differentiation rate (b), which 
is not biologically plausible during the brief exposure periods. There are several 
hypotheses on how radiation could affect promotion, such as negative selection (Mitchel 
and Trivedi 1992), genomic instability (Little 1998;Wright 1998;Kadhim et al. 2001), and 
bystander effect (Little and Wakeford 2001) - all of which would explain how a brief 
exposure could result in lasting effect of the radiation (Little 2000). 
From the results presented here, we see that at low doses, the Cox proportional 
hazards model and the two-stage clonal expansion model (although from completely 
different theoretical backgrounds and likelihood equations) resulted in similar 
descriptions of this data and estimated risk. This is because when IOg(J.!I) is the only 
parameter with a slope coefficient ( b), the two-stage model satisfies the proportional 
hazards model. The difference is in the interpretation of the models and their parameters 
and baseline hazard estimation process. The Cox proportional hazards model does not 
specify the baseline hazard function while in the two-stage model the baseline hazard is a 
function of the constant terms of the parameter estimates, giving biological meaning to 
the baseline hazard. 
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CONCLUSION: 
The main conclusion that can be drawn from these analyses is that the empirical 
and biologically based dose response models resulted in very similar descriptions of the 
low dose data. The two-stage clonal expansion model with J.ll dependent on dose 
satisfies the proportional hazards assumptions. Therefore the main difference in the two 
models is how the background hazard is calculated and the interpretation of the 
parameters, the empirical values results in a description of the dose effect while the two-
stage model allows inferences to be drawn about the background hazards and parameter 
estimates that relate to the stage of carcinogenesis affected by dose. 
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APPENDIX: 
Two-stage Model Estimation Methods 
Let Xo denote the number of normal susceptible cells in Figure 1. Xo is assumed 
large and constant in the study period and J..ll=UXO, where u denotes the first initiation 
rate per unit time per cell from the nonnal to intennediate cell. The survivor function 




J-ll {t(R+P-8- J1 2) 1 R-(f3- 8 -J.l2)+(R+f3-<5-J.lZ)e-Rt} t = - + og-----~---------:::..-~~ 
~ 2 2R 
[A.I] 
with 
(Moolgavkar I 986;Kopp-Schneider et al. 1994). The three parameters 
are identifiable, and the 0/, a net-proliferation rate, and p, an overall mutation rate, are 
discussed in applications (Moolgavkar et al. 1999;Heidenreich et al. 1997a). However, 
the complicated fonn of [A.I] often results in numerical problems in detennining the 
precise MLE of the parameters. 
Thus, Leenhouts et al set ()=Q in [A. 1] that results in 
A( ., A'" ... 5:=0)= J.t; [A* 1 {J.!; + ~., exp{- (13'" + f-l~) }}] t, J..lI ,t--J ,f.l2 ,u * I-' t + og * * 
~ f3 +f.12 
[A.2] 
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To distinguish between the parameters assuming 8=0 and the original parameters, 
J.l: ,J3 '" and Jl; are used in [A.2] (Leenhouts 1999). Leenhouts et al (1999) regard f3'" as 
a net-proliferation rate. 
Nakamura and Hoel (unpublished paper) obtain the following exact relationships 
... 
R"'· ... '" ]..11 
'V == p - Jl2' P = }ll Jl z ' and 11 = ~* 
J3 
[A.3] 
Thus, MLE of the parameters 'V, p and 11 can be obtained from those of I-l; ,f3 '" and 11; 
using the simple transformation. Since Jl; is usually much smaller than ~*; 'If == ~* 
should approximately hold. 
Briefly, advantage of using [A.2] over the original [A. I ] is that appropriate initial 
trial values may be obtained from two-dimensional grid tables and the iteration searching 
for the MLE converges even in the method based on [A. I] fails to converge. More 
detailed comparison between [A.1] and [A.2] is dealt with in Nakamura and Hoel 
(unpublished paper). 
Since the parameters take only positive values, we applied a log-linear model for 
each parameter, 
logeS) = a+bDose [A.4] 
where Dose denotes the exposure doses and a and b denote a constant tenn and a slope 
coefficient, respectively. As for the overall mutation rate p, 
log(p) = logXovJ-l2 = a+bDose. 
Since Xo is constant independent of Dose, we have 
log(VJ.12) = a-IogXo+bDose. 
That is, the slope coefficient b implies the effect of Dose on the over all mutation rate per 
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unit time per cell, VJl2, independent of the number of normal cells Xo. The unit time is 
day, and the target tissue is whole body in the radiation data. 
The model with only a constant term a for each of the three parameters J..lI, f3 and 
J..l2 is referred to as base model. The base model is independent of the exposure dose. 
We obtained the significance of the slope term b for each parameter based on the 
likelihood ratio test, relative to the base model, in a stepwise manner. It is 
straightforward that the model with 109(J.!l) = a+bDose, but no slope other terms (for 
log(~) and log(J.!2)) satisfies the proportional hazards assumption. 
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6.3 Comparison of Two Models of Risk Estimation: Part II 
ABSTRACT: 
The analyses in this paper are based on an expanded subset of the experimental 
mortality data used in Part 1. The data comes from experiments using male and female 
B6CF 1 mice, conducted at the Argonne National Laboratory, to study the effects of 
exposure to whole-body irradiation to assess the shape of the dose response curve and the 
effects of dose fractionation. The mice were grouped based on their sex, exposure pattern 
(single exposure or 60 once-weekly exposures) and total accumulated dose of exposure 
with doses ranging from 0 cGy to 1839 cGy for gamma exposure and 0 cGy to 226 cGy 
for neutrons. The two-stage model and the Cox proportional hazards model are used to 
compare the results of an empirical model with a model based on biological information 
on the carcinogenesis process. Both the neutron and gamma dose response curves appear 
linear at the lower doses (less than 30-40 cGy), before the nonlinearities become evident. 
The findings suggest a reduction in the effectiveness of gamma irradiation with 
fractionation, while the effectiveness of neutrons increases with fractionation. 
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INTRODUCTION: 
The previous paper (Part I) used a subset of the Argonne National Laboratory 
(ANL) experimental mortality data of B6CF1 mice exposed to external whole body 
radiation with doses of gamma rays less than 300 cGy and fission neutron less than 30 
cGy. In the current analysis, the data set is expanded to include high doses with dose 
fractionation. The dose response curves are examined for the entire dose range (86 cGy -
1839 cGy gamma and 1 cGy -226 cGy neutron exposure) and the low dose region is 
compared with the results from the restricted data used in Part I. To enable the 
comparison of the different models, exposure patterns, and cancer types, the various 
populations were truncated at a date when mice were still alive in all exposure groups, 
which in this study included higher doses; therefore, the survival times are censored at 
850 days (approximately 28 months) from the date of initial exposure instead of three 
years as in Part I. 
MATERIALS AND METHODS: 
The material and methods used in this paper are described in detail in the previous 
paper. Below is a brief description of the data and statistical methods. 
The data used in these analyses is from the database compiled on the response of 
male and female B6CF. mice to external whole body gamma, neutron, or sham 
irradiation from the Biological and Medical Research Division at ANL (Grahn et al. 
1995). The same data set (macroscopic data), exposure patterns (single exposure and 60 
once-weekly exposure) and diagnosis classification (caused or contributed to death) were 
investigated. A summary of the number of mice, their mean survival time, and the cases 
of cancer for each dose group and exposure pattern is given in Table 1. 
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Table 1 - Summary of the mice included in the analyses: Exposure pattern, Dose (cGy), Number of 
mice, Mean age at death (± SE), Number of cases of solid tumors and lymphoreticular tumors 
(percent). 
Exposure Dose a Number 
MAD b Cancer Cases (Percent) 
Pattern of Mice (+SE) ST C LRT d 
0 713 967.76 (+ 7) 326 (46) 209 (29) 
86 571 940.95 (+ 8) 287 (50) 157 (27) 
137 150 947.18 (±17) 71 (47) 43 (29) 
Single 
198 308 923.68 (±11) 150 (49) 112 (36) 
Gamma 
Exposure 257 179 837.67 (±14) 77 (43) 61 (34) 
400 117 864.03 (±17) 49 (42) 38 (33) 
546 118 758.68 (±21) 34 (29) 40 (34) 
756 184 593.42 (± 9) 31 (17) 60 (33) 
0 858 990.01 (+ 7) 385 (45) 351 (41) 
100 562 979.45 (± 7) 233 (42) 275 (49) 
60 Once- 200 164 967.52 (±13) 67 (41) 72 (44) 
Weekly 
Gamma 
300 76 924.26 (±21) 30 (40) 38 (50) 
Exposure 450 82 906.99 (±20) 31 (38) 39 (48) 
600 80 908.15 (±20) 33 (41) 40 (50) 
1839 139 757.01 (±12) 52 (37) 50 (36) 
0 1725 971.39 (+ 5) 499 (29) 741 (43) 
1 661 987.82 (+ 8) 181 (28) 320 (48) 
2 411 973.04 (+ 9) 124 (30) 190 (46) 
5 312 949.01 (+12) 102 (33) 120 (39) 
Single 9 230 931.75 (+13) 83 (36) 77 (34) 
Neutron 
Exposure 19 780 892.80 (± 7) 296 (38) 276 (35) 
38 142 869.21 (±16) 69 (49) 45 (32) 
75 185 788.67 (±14) 63 (34) 47 (25) 
151 117 759.60 (±17) 53 (45) 28 (24) 
226 187 697.38 (±13) 54 (29) 35 (19) 
0 705 991.22 (± 7) 187 (27) 399 (57) 
2 520 986.84 (± 8) 134 (26) 295 (57) 
60 Once- 8 204 975.03 (±11) 58 (28) 115 (56) 
Weekly 14 219 924.02 (±11) 71 (32) 110 (50) 
Neutron 22 225 912.86 (±11) 65 (29) 128 (57) 
Exposure 31 135 905.47 (±14) 45 (33) 64 (47) 
41 76 837.08 (±18) 32 (42) 29 (38) 
151 152 742.46 (± 9) 68 (45) 41 (27) 
a- Total accumulated dose measured in cGy 
b- Mean age at death (MAD) given in days plus or minus the standard error (± SE) 
c- Solid Tumors (ST) 
d- L ymphoreticular Tumors (LR T) 
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Statistical Methods 
The investigation consists of the same basic approach to analyze the dose 
response of three different cancer endpoints and compare the results as were used in 
Part 1. Of interest in these analyses are primary tumor, lymphoreticular tumor, and solid 
tumor - where primary tumor is the equivalent to "all cancer endpoints" and can be sub-
grouped into lymphoreticular ("all leukemia and lymphoma") and solid ("all cancers 
other than leukemia and lymphoma") tumors. 
The Cox proportional hazards (Cox 1972) model was used to investigate the 
empirical relationship between dose and cancer. Four functions were evaluated for the 
parametric form of dose to be used in the model; linear dose (D = dose), quadratic dose 
linear-quadratic dose and log-linear dose 
CD == log [dose ]). The two-stage clonal expansion model parameters (8) were adjusted 
to allow for a quadratic term before the log-linear transformation is applied to the 
parameters 
D2 
log( 8) == a + ho D+ hi -
100 
where D is the total accumulated gamma or neutron dose, a is a constant term, and bo 
and b I are regression coefficients (Moolgavkar 1986). 
The relative biological effectiveness (RBE) and dose rate effectiveness factor 
(DREF) are dose weighting factors used to describe the differences in biological effect 
for radiation qualities and dose rates. They are calculated based on the initial slope 
estimates, which for the non-linear and computed from the dose response curves 
(Committee on the Biological Effects of Ionizing Radiation NRC 1990). 
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RESULTS: 
To determine the function of dose to be used for each cancer type and exposure 
pattern the Akaike's information criterion (AIC) scores (Aka ike 1976) were evaluated for 
each and are presented in Table 2, with the lowest Ale score marked in boldface. We see 
that the linear function of dose is the best fitting model for gamma exposure irrespective 
of the cancer endpoint, while the linear-quadratic fits better for neutron irradiation. The 
only example where this does not hold true is for lymphoreticular tumors following acute 
neutron exposure, where the linear model is slightly better, but not significantly different 
from the linear-quadratic function. Therefore when comparing the results with the two-
stage model the linear fonn is used for gamma exposure and the linear-quadratic [onn is 
used for the neutron exposure. 
Table 2 - Akaike Information Criterion (AIC) scores for the Cox proportional hazards model for each 
cancer endpoint examined. The four functional forms of dose evaluated are the Linear (L), Quadratic (Q), 
Linear-Quadratic (L-Q), and Log-Linear (L-L) functions of dose for each exposure pattern 
Radiation Exposure Ale Score a 
Quality Pattern L Q L-Q L-L 
Primary Tumors 
Gamma 
Single 15028.68 15035.24 15028.76 15106.02 
Fractionated 11904.19 11914.53 11905.35 11971.22 
Neutron Single 29306.62 29367.03 
29268.34 29279.31 
Fractionated 14122.37 14155.58 14106~38 14147.58 
Lymph ore ticular 
Tumors 
Gamma 
Single 5992.56 6001.42 5993.73 6076.81 
Fractionated 6084.90 6091.28 6086.12 6121.56 
Neutron 
Single 16361.78 16368.85 16362.97 16369.14 
Fractionated 9184.90 9195.69 9178.91 9184.19 
Solid Tumors 
Gamma 
Single 9003.20 9006.17 9005.18 9012.18 
Fractionated 5821.11 5825.14 5822.95 5851.47 
Neutron 
Single 12917.45 12983.81 12858.12 12925.62 
Fractionated 4907.53 4932.34 4893.50 4927.85 
a The smallest AIC Score represent the form of the model that best fits the data and is represented in bold 
face. 
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Radiation can affect the initiation rate, promotion rate, progression rate, or any 
combination of these three rates in a linear, quadratic, or linear-quadratic manner. 
Therefore, there are six different dose related parameters to consider in selecting the 
optimal model. To determine which of the parameters to include in our model, a 
stepwise selection procedure was performed in which we found the best model based on 
the log likelihood at each level of parameters, and then performed likelihood ratio tests to 
see if the additional parameter significantly improved the fit of the model. 
The models that describe the entire dose range are more complicated, and in most 
cases, requiring more parameters (quadratic terms) to describe the data than was the case 
when only low doses were considered in the model (Part I). The fractionated gamma 
exposure the models were an exception, they were best described by a linear promotion 
model (~ is the only dose dependent parameter included in the model). For most of the 
other exposure patterns and cancer endpoints the model suggests that there are both 
initiation and promotion effects in the radiation induced carcinogenesis process. 
The single exposure patterns all have a positive initiation parameter and a 
negative promotion parameter, indicating an increasing initiation and decreasing 
promotion with increasing dose; the models for fractionated exposure patterns have a 
positive promotion parameter. The neutron exposure models, both the acute and 
fractionated patterns, have a negative quadratic parameter estimates that causes a 
downward curve in the dose response at higher doses, similar to a negative quadratic tenn 
in the Cox linear-quadratic model. 
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Table 3 - Parameter Estimates for the two-stage clonal expansion model for each exposure pattern (Exp) and dose range examined. 
ExpU Cancer b IOg(J.l1 *) log «(3*) log (J..L2*) 
'" bo b I bo b1 bo hI a a a 
Pr_T -4.8929 0.00152 0.00043 -4.8137 0.00031 -0.00021 -12.0559 -- --
G1 Lr_T -5.2876 -- 0.00005 -4.8130 -- -0.00023 -13.0443 -- --
S T -5.6721 0.00280 -- -4.6858 -0.00050 -- -12.0836 -- --
Pr_T -4.6695 -- -- -4.7387 0.00022 -- -12.7101 -- --
G60 Lr_T -5.3706 -- -- -4.7312 0.00023 -- -12.7190 -- --
S_T -5.3483 -- -- -4.7485 0.00021 -- -12.6992 -- --
Pr_T -4.6528 0.04920 -0.0055 -4.8684 -0.00256 -- -12.2134 -0.0251 --
N1 Lr_T -5.4542 0.03107 -0.0071 -4.7575 -0.00600 -- -12.3611 -- --
S_T -4.9557 0.02547 -0.0082 -4.9682 -- -- -12.5299 -- --
Pr_T -4.6801 0.00333 -- -4.7372 0.00612 -0.0027 -12.8313 -- --
N6D Lr_T -5.2419 -- -- -4.6491 0.00545 -0.0024 -13.0251 -- --
S_T -5.4325 0.00585 -- -4.8658 0.00815 -0.0036 -12.7533 -- --
a Exposure Patterns (Exp) are Gamma Single (01), Gamma Fractionated (060), Neutron Single (Nl) and Neutron Fractionated (N60). 
h Cancer types are Primary tumor (Pr_T), Lymphoreticular tumor (Lr~T) and Solid tumor (S~T) 
'* Each parameter is modeled as logeS) = a + baD + b 1(D 2/lOO). (--) value indicates that the parameter was not included in the model. 
I 
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Plots of the log risk versus total accumulated dose are used to depict the shape of 
the dose response curve for the each cancer type. In Figure 1, we examine the primary 
tumor dose-response curve for each exposure pattern. The Cox proportional hazards 
model (-) estimates the relative risk, while the two-stage model (---) estimates the 
absolute risk. Therefore., for comparison purposes, without affecting the meaning of the 
curves, the relative risk curves are adjusted to the absolute risk for the control group 
(dose = 0). The Kaplan-Meier observed risk ( • ) and the 95% confidence interval are 
plotted for each dose group as a reference. Figures 2 and 3 are similar plots for the cancer 
endpoints lymphoreticular tumors (Figure 2) and solid tumors (Figure 3). 
The neutron dose response curves (Figures C and D) indicate that at doses 
between 40 and 50 cGy, the neutron dose response curve starts to bend downward the 
effect of the negative quadratic term in the models, as described above. The dose effect 
of a single exposure to neutrons is less noticeable for lymphoreticular tumor (Figure 2C), 
the slope is not as steep and only the two-stage model indicates a bend, but not until 
higher doses (80 to 90 cGy); the Cox proportional hazard model is linear. When the 
doses were restricted to the low dose range «30 cGy), the dose effect for 
lymphoreticular tumors following an acute neutron exposure was not statistically 
significant (p=O.24). The dose response curve is shown in Figure 4. 
In Figure 5 the low dose region of the primary tumor dose response curves from 
this paper (entire dose range) are plotted against the estimates from the low doses 
(ganuna <300 cGy and neutron <30 cGy) in Part I. The results for the entire dose range 
are given in red, while the low dose range are denoted in blue. Although they look 
similar, their interpretations can be different. In comparing gamma single to gamma 60 
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once-weekly exposures (Figures 5A and 5B) both dose ranges indicate a reduction in the 
effectiveness due to fractionation, but for neutron exposure (Figures 5C and 5D) the 
entire dose range and low dose range result in disparate descriptions on effects of 
fractionation. There is an indication of an increased effect of fractionation when the 
entire dose range is included in the analysis, while there is no noticeable affect of 
fractionation when the analysis is restricted to the lower doses. 
The RBE estimates and standard errors (Table 5) for these analyses, as in Part I, 
are for the purposes of comparing the Cox proportional hazard and two-stage models, 
because they are not adjusted for gender. The two models indicate similar patterns in the 
RBE values, with values ranging from 1.41 to 23.77 for acute exposures and 24.98 to 
46.35 in the case of fractionated exposures. This increase in the RBE values with 
fractionated exposures is largely due to the reduced effectiveness of gamma with 
increased fractionation. These values are consistent with values obtained from previous 
studies, which have ranged from 2 to 100 depending on dose, dose-rate, energy, cell or 
tissue culture, and cancer type. As seen in previous studies life shortening studies the 
RBE for lymphoreticular tumors are generally lower than some subtypes of solid tumors 
and the values for acute exposure are less than fractionated exposures due to the change 
in effectiveness with fractionation (Carnes et al. 1989). 
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Table 4 - Estimates of the neutron relative biological effectiveness (RBE) and standard error for 
primary, Iymphoreticular, and solid tumors for each model and exposure pattern 
Model Exposure 
Primary Tumor Lymphoreticular Solid Tumor 
Pattern RBE SE RBE SE RBE SE 
CPH Single 8.52 1.02 1.49 0.25 22.46 4.66 
Fractionated 34.15 5.38 24.98 6.22 46.35 10.35 
TSM 
Single 7.06 0.77 1.41 0.18 23.77 3.90 
Fractionated 33.9 4.01 25.02 5.26 43.95 8.52 
The models are the Cox proportional hazards model (CPH), the piece-wise linear Cox model (PWC) and 
the two-stage model (TSM). 
In Table 5, the dose rate effectiveness factors for gamma and neutron irradiation 
are given for each cancer endpoint investigated. In general, the two-stage model and Cox 
proportional hazards model give similar results for gamma and neutron DREF for each of 
the cancer sites. Fractionation reduces the effectiveness of gamma exposure, but 
increases the effectiveness of neutron exposure similar to the finding from previous 
studies on life shortening (Carnes et al. 1989), tumor mortality (Grahn et al. 1986), and 
neoplastic transfonnations (Hill et a1. 1985). When only low doses were used in the 
analysis (Part I) there was no notable difference between the effectiveness of single and 
fractionation neutron exposure. The DREF value estimated by the two-stage model for 
lymphoreticular tumors is larger than the estimate based on the Cox proportional hazards 
model. This is due to the curvelinear nature of the two-stage model (Figure 2A). 
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Table 5 -Estimates of the dose rate effectiveness factor (DREF) and the Upper (U) and Lower (L) 
standard error for primary, lympboreticular, and solid tumors for each model and radiation quality 
Model Radiation Primary Tumor Lymphoreticular Solid Tumor 
Quality DREF (U, L) DREF (U, L) DREF 
CPH Gamma 2.53 (2.27,2.83) 3.65 (3.19,4.15) 1.53 
Neutron 0.64 (0.54,0.75) 0.22 (0.17,0.30) 0.65 
TSM 
Gamma 2.85 (2.59,3.14) 5.76 (5.33,6.22) 1.22 
Neutron 0.64 (0.55,0.74) 0.29 (0.25,0.35) 0.68 
The models are the Cox proportional hazards model (CPH), the two-stage model (TSM) 






The risk estimates for primary tumors, lymphoreticular tumors and solid tumors 
are given in Table 6, as well as the risk estimates for primary tumors from Part I. The 
most notable discrepancy in the risk estimates is for the risk of lymphoreticular tumors 
from an acute exposure to gamma irradiation, where the two-stage model estimates a 70 
% larger relative risk at 100 cGy (1 Gy) exposure. This is due to the curvilinear nature 
of the two-stage model dose-response, at 450 cGy the results are approximately reversed 
and the Cox model estimates a 70% larger relative risk than the two-stage model. 
The risk estimates indicate that there is very little risk from highly fractionated 
gamma exposures, which is agrees with the finding from the Canadian fluoroscopy study 
for lung cancer mortality (Howe 1995). This is interesting because the majority of the 
solid tumors in the JANUS data are lung cancers. The relative risk estimates based on 
the mortality studies of the atomic bomb survivors (Pierce et a1. 1996) are risk estimates 
for an acute exposure to a combination of neutron and gamma irradiation, but at doses of 
1 Gy the exposure is predominantly gamma rays. The estimated relative risk by gender 
for solid tumors was 1.17 (male) and 1.44 (female)~ these values are comparable to the 
ganuna single exposure in our study (which are male mice). 
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Table 6 - Relative Risk estimates for 100 cGy gamma and 10 cOy neutron radiation exposure for the Cox 
proportional hazards model (CPR), two-stage clonal expansion model (TSM) and the piece-wise linear Cox 
model (PWM) for primary tumors, lymphoreticular tumors and solid tumors 
Exposure Model Relative Risk Estimate Pattern Primary (Low Dose) Lymphoreticular Solid 
Gamma 
CPH 1.21 (1.20) 1.33 1.12 
Single TSM 1.26 (1.22) 1.57 1.11 
PWM 1.19 1.13 N/A 
Gamma CPH 1.08 (1.13) 1.08 1.08 
Fractionated PWM 1.10 (1.12) 1.10 1.09 
Neutron 
CPH 1.12 (1.26) 1.07 1.27 
Single TSM 1.19 (1.26) 1.07 1.28 
PWM 1.25 N/A 2.01 
Neutron CPH 1.29 (1.28) 1.21 1.46 
Fractionated TSM 1.32 (1.27) 1.26 1.46 
Relative risk estimates for primary tumor are given as the relative risk for all doses with the relative risk 
estimates from when only low doses are included in the analysis in parentheses 
DISCUSSION: 
We see that in most cases the Cox proportional hazards model and two-stage 
clonal expansion model result in similar dose response curves, risk estimates, and 
weighting factors to describe the effect of radiation qualities and dose rates. But there are 
advantages of using a biologically based model, like the two-stage model such as - they 
necessitate a better understanding of the disease process being studied, the parameter 
estimates have biological interpretations, and they increase the credibility of the risk 
assessment (Goddard and Krewski 1995). 
It has been generally accepted that the majority of the biological consequences 
associated with ionizing radiation are due to a direct interaction with DNA, altering the 
replication and repair process. There are many types of radiation induced DNA lesions, 
but misrepaired double strand breaks are considered the essential lesion in the induction 
of both chromosomal abnormalities and gene mutations (Ward 1995). Of these 
chromosomal abnormalities and gene mutations it has been suggested that the 
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inactivation of a tumor suppressor gene, by loss of heterozygosity, is most likely to be the 
initiating event in radiation carcinogenesis (Little 2000). 
For single exposures to gamma and neutron irradiation we see a positive initiation 
effect combined with a negative promotion effect. It has been hypothesized that in the 
presence of a strong initiator, such as radiation, an increase in apoptosis would 
accompany the increase in initiated cells due to initiation, in order to keep the number of 
intennediate cells in check (Nakamura and Hoel 2002). 
The results for most cancer types and exposure patterns indicate that part of the 
risk from exposure to radiation is its effect on the net proliferation rate, promotion effect. 
Although it has been suggested that it would not be biologically plausible for a brief 
exposure to induce the increased growth imbalance necessary to see a promotion effect, it 
has been proposed that radiation inactivates or kills cells, which are then replaced by the 
division of neighboring cells. Since initiated cells have a growth advantage over nonnal 
cells they fill the void faster than normal cells (Heidenreich and Hoogenveen 2001). 
The brief exposure periods experienced by the animals in the JANUS program are 
quite different from the extended exposure periods used to define chemical 
carcinogenesis. Therefore a biological rationalization is needed to explain how radiation 
can cause a change in the parameter values that is constant throughout the entire study 
period. Recent studies have indicated that radiation may induce some indirect genetic 
consequences in cells that themselves do not receive direct nuclear radiation. Currently 
three areas of research into this phenomenon are: radiation induced genomic instability, 
bystander effect, and cytoplasmic irradiation. The tenn genetic instability is used to 
describe a transfonnation, characteristic of a mutagenic event, which may occur in the 
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progeny of an irradiated cell, even after many generations of cell replication. This lead to 
the hypothesis that radiation induces a transmissible genetic instability that has the effect 
of enhancing the rate of transfonnation in the descendents of an irradiated cell (Little 
2000;Mothersill and Seymour 1998). Bystander effect implies that persistent, genetic 
alterations can occur in nonirradiated cells due to damaged signals transmitted by 
neighboring irradiated cells (Little 2000). Furthennore studies have been demonstrated 
links between a bystander effect and genomic instability; chromosomal instability has 
been detected in the progeny of nonirradiated cells (Watson et al. 2000). Cytoplasmic 
irradiation has been shown to induce a significant increase in the spontaneous mutation 
frequency, while having little effect on cell survivaL These phenomenons could play 
important roles in the carcinogenic effects at lower doses, where fewer cells are in direct 
contact with the radiation (Lewis et al. 2001) and would increase the probability that a 
cell could accumulate the mutational events necessary to give rise to a malignant tumor 
(Kadhim et al. 2001 ;Little 1998). These findings indicates that the carcinogenic effects 
of ionizing radiation is not restricted to the direct interaction with DNA and suggest that 
radiation could act as a chronic exposure. 
There is a noticeable downward curvature at higher doses of the dose response 
curves for neutron exposure. This type of curvature has been seen in this and other 
mouse data for life shortening effects (Storer and Fry 1995) as well as in the Atomic 
bomb survivorship data (Shimizu et a1. 1990). Cell killing is the likely explanation of the 
downward curvature at higher doses. It has been shown that a linear model with an 
exponential cell killing tenn can be used to describe a linear-quadratic model, where the 
negative quadratic term indicates cell killing. Although this cannot be estimated directly 
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by the Cox proportional hazards model, it provides an adequate fit to the Cox dose 
response curve (Figure 6). The two-stage model does not include a parameter for cell 
killing and therefore it is not possible to separate the effects of cell killing from the other 
effects estimated in the model. 
Inferences made about the mechanism of actions of an agent based on these 
analyses must be taken cautiously. Because although the two~stage model is useful in 
generating hypotheses about the underlying mechanism of carcinogenesis, it has been 
shown that tumor incidence data does may not have the power to distinguish between 
initiating and promoting effects (Portier 1987). 
CONCLUSION: 
These analyses suggest that the empirical and biologically based models result in 
similar, linear descriptions of the low dose region of the dose response curve. The 
difference in the two models is seen for single exposures to gamma irradiation with 
respect to lymphoreticular tumors in which the two-stage clonal expansion models 
predicts a steeper initial slope of the dose response curve, and therefore a higher DREF 
and risk of cancer than the Cox proportional hazards model. The parameterization of the 
two-stage model suggests both the initiation and promotion effects are involved in 
radiation induced carcinogenesis. 
The dose range used in the analysis affected the RBE and DREF values for both 
models, but did not have much effect on the estimates of risk. When the entire dose 
range is analyzed the RBE for acute exposures is slightly lower than for the low dose data 
while the fractionated exposures results in high RBE values. These values are typical of 
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the RBE values found in other studies, which have ranged from 2 to 100. The results 
suggest that neutrons exposure appears to have more effect on solid tumors than gamma 
irradiation (RBE approximately 3 times higher for solid tumors than for all cancers 
combined) and a very small effect on lymphoreticular cancers (RBE almost 1.5). The 
DREF values indicate a reduction in the effectiveness of gamma irradiation with 
fractionation, while the neutron indicated an increased effectiveness when the entire dose 
range is analyzed. 
The resulting nonlinearities in the dose response curve become evident at higher 
doses as has been seen in life shortening studies. In particular the dose response curves 
for the different cancer endpoints following neutron exposure bend downward at higher 
doses, possibly indicating a cell killing effect. To determine the best approaches to 
radiation protection, the issue of non-linearity in the dose response curve will have to be 
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Figure 6 - Plot of log(risk) of primary tumors following exposure to neutrons. Linear quadratic Cox Proportional Hazards (CPH) 
(-)~ a linear with cell killing (---) line fit to the Cox estimated dose response curve, and the Kaplan-Meier plot of the observed 








The purpose of this research was to evaluate the low dose region of the dose 
response curve for cancer risks from ionizing radiation. Although this has been examined 
and reported in the past, errors in the dose estimates have been shown to alter the shape 
of the dose response curve at low doses. In the analyses of the atomic bomb data the 
appropriate corrections were made to the dose estimates and the models fit to the 
corrected dose to see if previous findings indicating non-linearities at low doses were still 
found or if they were simply an artifact of the errors in the dose. 
In Paper I a threshold was included in the model, as a surrogate for non-linearity. 
The threshold model was found to significantly improve the fit of the solid tumor 
incidence model when the doses are adjusted for uncertainty and systematic neutron 
error, and the neutron RBE is considered dose-dependent. The non-linearity that was 
seen previously in the uncorrected leukemia incidence data was still present after the dose 
adjustments, therefore providing further support for the use of a non-linear model at low 
doses. The mortality data did not indicate a significant improvement in the fit of the data 
although, the threshold and no threshold models were indistinguishable at lower doses. 
Only the solid tumor incidence data did not indicate an improvement with the addition of 
a threshold, similar to the results of the uncorrected doses. 
Papers II and III look at the ANL mouse data to gain insight into the modifying 
effect of fractionation on gamma and neutron exposures. In Paper II only the lower 
doses were included in the analyses, and resulted in a linear models for both radiation 
qualities, independent of the exposure pattern. The two-stage model was best fit with the 
J..ll model in which initiation was the only stage dependent on dose. Both models, the Cox 
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proportional hazards model and the two-stage clonal expansion model resulted in the 
same description of the data, with the two-stage model reducing to a proportional hazards 
description of the data when J.lI is the only dose dependent parameter. At low and high 
doses fractionation reduced the effectiveness of gamma irradiation while, the 
fractionation of neutron produced results that were dependent on the dose range being 
examined. In the analyses of the data restricted to low neutron doses there was no change 
in the effectiveness of neutrons due to fractionation but when the entire dose range was 
included the results indicated that there was an increase in their effectiveness. The 
models that best describe the data for the entire dose range are much more complicated 
than those for the low doses. The Cox proportional hazards model fit the linear-quadratic 
tenn to the neutron exposures and the two-stage model indicates that both the initiation 
and promotion effects are needed to describe the carcinogenesis process following 
ionizing radiation exposure. 
It remains to be detennined how many of the recent advancements in the 
understanding of radiation biology are going to affect the issue of non-linearity in the low 
dose region of the dose response curve. The issue will in the future influence the 
approached to radiation protection. 
Limitations 
• A-bomb Data 
• Data available is grouped by city, sex, dose, age at exposure and calendar 
time; therefore we are correcting the average gamma and neutron dose and 
calculating the dose-dependent RBE based and the corrected average doses. If 
the corrected average dose moves up into the next dose group then the entire 
- 116 -
7. Summary 
group is moved up. As well, there is no variability associated with the 
average dose. 
• The entire cohort is Japanese and exposed at one time. This reduces the 
ability to extrapolate the results to other populations from different times. 
Because there are genetic components of cancer risk, and cancer risk have 
been shown to change over time. 
• There are uncertainties that are associated with the correction factors and 
methods that cannot be separated. 
• JANUS Mouse Data 
• The study is retrospective therefore the data was collected with other studies 
in mind and we are using it to explore the effects of fractionation at low doses. 
Therefore we have to deal with the data that is available. There are not many 
truly low doses available in the gamma exposures. In fact the lowest dose 
available is 86 cGy for the single exposures and 100 cGy for the fractionated 
exposures. This means that any non-linearity that may occur at smaller doses 
(as seen in the A-bomb study at approximately 20 cSv) would be missed in 
these analyses. As well, the doses available did not pennit us to explore the 
effect of radiation quality within the same sex. The gamma exposures were 
restricted to male mice and the neutron exposures were only female mice. 
• Could not look at possible trend with increasing fractionation because the 24 
once-weekly exposure data did not contain data for low doses. 
• Inferences made about the mechanism of actions of an agent based on these 
analyses must be taken cautiously. Because although the two-stage model is 
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useful in generating hypotheses about the underlying mechanism of 
carcinogenesis, it has been shown that tumor incidence data does may not 
have the power to distinguish between initiating and promoting effects. 
Future Work 
• A-bomb Data 
• Analysis with data on the neutron activation measurements for a more 
accurate correction 
• Include Nagasaki to see if dose corrections for both cities bring the predictions 
of risk inline with one another. (Includes collection of copper samples in 
Nagasaki to allow for neutron activation measurements) 
• Use of individual data to for the dose corrections 
• Mouse Data 
• Apply models to a data set that included comparable doses for both sexes and 
radiation qualities 
• Adjust the model to account for the fact that fractionated doses are distributed 
over time. 
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